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ABSTRACT 
 
 
UDP-galactopyranose mutase (UGM) is a flavoenzyme which catalyzes the 
interconversion of UDP-galactopyranose (UDP-Galp) and UDP-galactofuranose (UDP-
Galf). UDP-Galf is the active precursor of Galf residues. Glycoconjugates of Galf 
residues are found in the cell wall of bacteria and on the cell surface of higher eukaryotes. 
Galf residues have not been found in humans and the fact that they are essential for the 
growth of pathogenic bacteria makes UGM a potential antibacterial target.  
In the present study, crystal structures of UGM from Deinocococcus radiodurans 
(drUGM) in complex with substrate (UDP-Galp) were determined. UDP-Galp is buried 
in the active site and bound in a U-shaped conformation. The binding mode and active 
site interactions of UDP-Galp are consistent with the previous biochemical and 
mechanistic studies. The mobile loops in the substrate complex structures exist in a 
closed conformation and Arg198 on one of the mobile loops stabilizes the phosphate 
groups of the substrate. The anomeric carbon of galactose is 2.8 Å from the N5 of FAD 
(in the reduced complex) favorable to form FAD-galactosyl adduct. In addition to 
substrate complex structures, the crystal structures of drUGM in complex with UDP, 
UMP, and UDP-Glc have been determined. The mobile loops in all these complexes exist 
in a closed conformation.  
Inhibitors for UGM were identified by ligand-based and structure-based methods. 
The phosphonate analog of UDP-Galp (GCP) showed only weak inhibition against 
various bacterial UGMs. The structure of drUGM in complex with GCP provided a basis 
for its inhibitory activity. Poor stabilization of the phosphate groups by conserved 
arginines (Arg198 and Arg305) and altered sugar binding mode account for its activity. 
 iii 
Novel indole-based (LQ1, LQ6 and LQ10) inhibitors of UGM were identified through 
structure-based virtual screening (SBVS) of a chemical library. Inhibition studies also 
allowed the identification of an active site aspartic acid that plays role in inhibitor 
binding.  
The structural studies on drUGM provided a basis for understanding substrate 
binding to UGM. In vitro enzyme inhibition studies allowed the identification of novel 
indole-based inhibitors. The structural and inhibition studies reported here enhance the 
understanding of UGM-ligand interactions and will assist in the development of more 
potent inhibitors of UGM.  
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 1 
CHAPTER 1 
     Introduction 
1.0 Bacterial cell wall as a drug target 
  The cell wall of bacteria is composed of proteins, lipids and carbohydrates and its 
architecture varies between Gram-positive and Gram-negative bacteria (Green, 2002). 
The cell wall of Gram-positive bacteria consists of a peptidoglycan layer and lipoteichoic 
acid (LTA). LTA extend through the peptidoglycan layer and appear on the cell surface 
(Figure 1-1a). In Gram-negative bacteria the cell wall is made of thin peptidoglycan layer 
and an outer cell membrane (Figure 1-1b) that contains lipopolysaccharides (LPS), 
phospholipids and proteins (Green, 2002). LPS O-antigen is an important virulence factor 
in Gram-negative bacteria and is required for resistance to complement-mediated serum 
killing (Joiner, 1988). The porins in Gram-negative bacteria regulate the passage of 
molecules across the outer membrane and are embedded within the lipid bilayer. In 
addition, Gram-negative bacteria also have a gel like periplasm between the cell wall and 
outer membrane. The cell wall of Gram-positive bacteria is thicker than the cell wall of 
Gram-negative bacteria. This is due to the presence of 20-fold more peoptidoglycan in 
Gram-positive bacteria. The cell wall of Mycobacterium tuberculosis, the causative 
organism of tuberculosis (TB), is a complex structure with an outer mycolic acid layer 
connected to the peptidoglycan through an arabinogalactan layer (Figure 1-2) (Pedersen 
& Turco, 2003; Weston et al, 1997). 
The bacterial cell wall helps in maintaining osmotic pressure inside the cell and 
protects the cellular components from the external environment. Also, the cell wall 
defines the shape of the cell. The integrity of the cell wall is critical especially during  
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Figure 1-1 Cell wall architecture of Gram-positive (A) and Gram-negative bacteria (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2 Schematic representation of the cell wall architecture of Mycobacterium to 
highlight the presence of Galf residues (GlcNAc = N-acetylglucosamine, Mur = Muramic 
acid. 
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cellular replication and growth. Any deleterious effect to the cell wall architecture can 
alter the cell wall integrity resulting in leakage of cellular components and eventually cell 
lysis. Thus, the bacterial cell wall is a potential drug target for developing novel 
antibacterial agents. Antibacterial therapeutics like penicillins and cephalosporins act by 
interrupting the cell wall biosynthesis.  
1.1 Biological significance of galactofuranose 
Carbohydrates are integral components of the cell wall of bacteria. Biochemical 
characterization of the cell wall components of various pathogenic microorganisms 
revealed the presence of a unique glycoconjugates made of D-galactofuranose (Galf) 
residues. For example, Galf conjugates are found in the LPS O-antigen of a number of 
pathogenic Gram-negative bacteria, including Klebsiella pneumoniae (Köplin et al, 
1997), Escherichia coli (Nassau et al, 1996), Shigella dysenteriae, Shigella boydii, 
Serratia spp., Actinobacillus pleuropneumoniae and Pasteurella hemolytica (Knirel & 
Kochetkov, 1994). In addition, Galf residues are essential components of the 
arabinogalactan layer of the Mycobacterium cell wall (Figure 1-1) (Weston et al, 1997) 
and are essential for their growth (Pan et al, 2001). Galf residues are also found in the cell 
wall and cell surface structures of other pathogenic micoroorganisms like Aspergillus 
(fungi) and Trypanosoma (protozoa) (de Lederkremer et al, 1980; Takayanagi et al, 
1994). Development of resistant strains of pathogenic bacteria to current antibacterial 
agents complicates treatment (Green, 2002). Furthermore, the treatment of TB is 
complicated by patient compliance, side effects, and emergence of multi-drug resistant 
(MDR) strains of M. tuberculosis to current anti-TB agents (Kremer & Besra, 2002). 
Hence, there is an urgent need to identify novel antibacterial drug targets and drugs 
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acting on them (Zhang, 2005; Green, 2002). Galf biosynthesis has been proposed as a 
potential target for developing novel antibacterial therapeutics (Pedersen & Turco, 2003).  
1.2. Role of UGM: Identification and Characterization 
  
Sugar residues like Galf are incorporated into the cell wall of bacteria by using 
sugar nucleotides as donor molecules. The sugar nucleotide, UDP-Galf  acts as a active 
precursor or donor molecule for Galf residues (Weston et al, 1997). UDP-Galf is 
synthesized from UDP-Galp by the enzyme UDP-galactopyranose mutase (UGM) 
(Weston et al, 1997). UGM catalyzes the reversible conversion of UDP-Galp (pyranose 
ring) and UDP-Galf (furanose ring) and the equilibrium favors the pyranose form over 
the furanose form (Figure 1-3) (Sanders et al, 2001; Zhang & Liu, 2000; Zhang & Liu 
2001). The first step in the biosynthesis of UDP-Galf (Figure 1-4) is the phosphorylation 
of Galp to form galactose-1-phosphate. In a subsequent uridylation step a UMP unit is 
incorporated into galactose-1-phosphate to form UDP-Galp. In the final step, UDP-Galp 
is converted to UDP-Galf by the action of UGM. Alternatively, UDP-Galp can be 
synthesized from UDP-glucose by the action of UDP-galactose-4-epimerase (Thoden & 
Holden, 1998). Upon formation of UDP-Galf various galactosyl transferases incorporate 
the Galf residues into the cell wall by using UDP-Galf as a sugar donor (Rose et al, 
2006). The fact that UGM is essential for the growth of certain pathogenic bacteria and  
 
 
 
 
 
 
Figure 1-3 UGM catalyzed interconversion of UDP-Galp and UDP-Galf. Equilibrium 
favors the pyranose (UDP-Galp) form over the furanose (UDP-Galf) form. 
UDP-Galp UDP-Galf
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Figure 1-4 Biosynthesis of UDP-Galf. UGM is found only in certain pathogenic 
microorganisms and have not been found in humans. 
 
its absence in humans suggests that UGM is an ideal target for developing novel 
antibacterial therapeutics. The genes encoding UGM in E. coli (ecUGM), K. pneumoniae 
(kpUGM), and M. tuberculosis (mtUGM) have been identified, cloned, expressed and the 
enzymes have been purified and characterized (Köplin et al, 1997; Nassau et al, 1996; 
Weston et al, 1997). ecUGM is the first enzyme from any organism demonstrated to 
catalyze the isomerization of pyranose form of a sugar to furanose form (Köplin et al, 
1997). UGM is a flavo-enzyme and contains the cofactor flavin adenine dinucleotide 
(FAD). FAD is bound to the enzyme non-covalently. The presence of FAD in UGM was 
shown by UV-visible spectroscopy with characteristic peaks at A382 and A450, with a 
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shoulder at A465 unique to FAD (Nassau et al, 1996). The purified fractions of UGM were 
yellow in color due to the presence of FAD. SDS-PAGE analysis and mass spectroscopy 
of ecUGM revealed the approximate molecular mass of the enzyme (about 45 kDa). 
Subsequent to the identification of ecUGM, the gene that encodes kpUGM was cloned, 
over-expressed, purified and characterized (Köplin et al, 1997). The molecular weight of 
kpUGM was found to be 45 kDa (by SDS-PAGE), similar to the molecular weight 
ecUGM. However, gel filtration analysis of kpUGM revealed a molecular weight of 92 
kDa, suggestive of a dimeric structure for the native enzyme (Köplin et al, 1997). The 
role of UGM in Mycobacteria was shown by  gene-knockout experiment using M. 
smegmatis as a model organism (Weston et al, 1997) and it has been shown that Galf 
biosynthesis is essential for growth. This suggests that mtUGM is a potential target for 
developing novel anti-TB drugs (Pan et al, 2001).  
1.3. Biochemical investigations on UGM 
Flavoenzymes are usually involved in the catalysis of redox reactions 
(Mansoorabadi et al, 2007). In case of UGM, the interconversion of UDP-Galp and UDP-
Galf does not change the redox state of the substrate, i.e.,  there is no net gain or loss of 
electrons in the reaction (Sanders et al, 2001). UGM activity was not observed in the 
absence of reductant NADH or NADP(H), suggestive of the need for the enzyme to be 
reduced for activity (Köplin et al, 1997; Nassau et al, 1996). Based on the ecUGM crystal 
structure, it has been proposed UGM does not have a specific binding cavity or pocket 
available for NADH or NADPH. In addition, sodium dithionite was also found to be an 
effective reducing agent for FAD in UGM (Sanders et al, 2001). Interconversion of UDP-
Galp and UDP-Galf was observed when sodium dithionite was used as a reducing agent 
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(Sanders et al, 2001). These preliminary investigations assign a specific role for FAD in 
the reaction mechanism. UGM activity experiments performed by adding the oxidant 
(K3FeCN6) to fully reduced UGM abolished its activity. These experiments clearly 
showed that oxidized UGM is inactive and only reduced enzyme is active (Sanders et al, 
2001). These studies assign a specific role for FAD in the reaction and it must be reduced 
for activity. The role of N5 atom of the isoalloxazine ring of FAD in UGM was 
demonstrated by reconstitution of UGM with the FAD analogs (Figure 1-5), 1-deaza-
FAD and 5-deaza-FAD (Huang et al, 2003). The activity of UGM reconstituted with 1-
deaza-FAD was comparable to the wild type, but the 5-deaza-FAD analog did not show 
any activity. Therefore, it is evident that N5 of FAD is critical for UGM activity and 
participates in the reaction mechanism.  
One of the proposed steps in the interconversion of UDP-Galp and UDP-Galf is 
the cleavage of the anomeric C-O bond (Barlow et al, 1999). Evidence for the cleavage of 
the anomeric C-O bond is supported by positional isotope experiments performed using 
labeled UDP-Galp (18O at anomeric position and 13C at C1 position). The cleavage of C-
O bond was monitored by detecting the isotopic shift accompanied by scrambling of 18O 
from the bridging position into a non-bridging position (Barlow et al, 1999).  
The mechanism of UGM reaction was further investigated using fluoro-
substituted substrate analogs as probes and also characterization of reaction intermediates 
(Soltero-Higgin et al, 2004). Based on these studies, three different mechanisms, namely 
SN1, SN2 and single electron transfer (SET), have been proposed (Figure 1-5 and 1-6) for 
the UGM reaction (Fullerton et al, 2003; Soltero-Higgin et al, 2004; Zhang & Liu 2001). 
The first step in the SN1 pathway involves the formation of an oxocarbenium ion by the  
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           Oxidized FAD            Reduced FAD 
 
 
 
         1-deaza-FAD      5-deaza-FAD 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5 FAD structure and proposed SN1 or SET pathways for UGM mediated 
interconversion of UDP-Galp. A) Structures of oxidized/reduced FAD and deaza-FAD 
analogs. B) Proposed SN1 or SET pathways for UGM mediated interconversion of UDP-
Galp and UDP-Galf. I, oxocarbenium ion; II, galactosyl radical; III, semiquinone form of 
FAD; IV, FAD-galactosyl adduct; V, iminium ion intermediate. 
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B 
 
 
 
 
 
Figure 1-6 Proposed SN2 pathway for UGM reaction. A) Concerted SN2 mechanism for 
UGM reaction. The intermediates (for example IV and V) are similar to the SN1 pathway. 
B) Sodium cyanoborohydride reduction of IV to form the adduct VI. Adduct VI is 
characterized by mass spectrometry.  
 
 
 
UDP-Galf
UDP-Galp
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cleavage of the anomeric C-O bond to release UDP. The reduced FAD acts as a 
nucleophile and attacks the C1 of the galactose (in oxocarbenium ion form) to form an 
FAD-galactosyl adduct. In a ring opening step, the FAD-galactosyl adduct collapses to 
form a iminium ion intermediate. Subsequently, the iminuim ion undergoes a ring closure 
to form an FAD-galactofuranose intermediate. In an SN1 manner, UDP attacks the C1 of 
galactofuranose (in oxocarbenium ion form) to form UDP-Galf. In support of SN1 or 
oxocarbenium ion formation, various fluoro-substituted analogs of UDP-Galp and UDP-
Galf have been synthesized and tested against UGM (Barlow & Blanchard, 2000; Zhang 
& Liu 2001). Presence of fluorine atom (2-fluoro and 3-fluoro substitution at the sugar 
moiety) would destabilize the oxocarbenium ion formation through inductive effect and 
may act as an inhibitor or poor substrates for UGM. Indeed, the fluoro-susbtituted 
analogs of UDP-Galp and UDP-Galf were found to be poor substrates for UGM, which 
indirectly supports the hypothesis that an oxocarbenium ion intermediate forms during 
the reaction. In a recent study, an open chain analog of UDP-Galp (UDP-Gal-OH) has 
been designed, synthesized and tested as a substrate for UGM (Itoh et al, 2007). The open 
chain analog did not show any turnover, but showed inhibitory activity towards UGM 
and this is considered as indirect evidence for SN1 pathway.  
An SN2 mechanism is also proposed for UGM reaction (Soltero-Higgin et al, 
2004), which involves the direct attack of N5 of FADH- on the anomeric carbon 
galactose to form an FAD-galactosyl adduct with simultaneous release of UDP. The 
FAD-galactosyl adduct then undergoes ring opening and ring closure reactions to form 
FAD-galactofuranose. In the final step, UDP attacks the C1 of galactofuranose to form 
UDP-Galf and regenerate the reduced FAD. The formation of the FAD-galactosyl adduct 
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has been demonstrated by reducing the iminium ion intermediate with sodium 
cyanoborohydride and the reduced intermediate characterized by mass spectrometry 
(Soltero-Higgin et al, 2004).  
Alternatively, the FAD-galactosyl adduct has been proposed to form via SET 
from reduced FAD to the oxocarbenium ion to form a galactosyl radical and the 
semiquinone form of FAD (Fullerton et al, 2003). The two radical species then 
recombine to form an FAD-galactosyl adduct. Potentiometric analysis of UGM provides 
evidence for the stabilization of the semiquione form of FAD upon binding of the 
substrate and also suggests that the fully reduced flavin in kpUGM has anionic character 
(FADH-) (Figure 1-5). The proposed SET pathway has been challenged on the basis of 
the redox potential of oxocarbenium ion and the FAD (Soltero-Higgin et al, 2004). The 
midpoint reduction potential of UGM was found to be -97 mV. Although the reduction 
potential of cylic galactose oxocarbeniuim ion is unknown, the midpoint potential of 
protonated formaldehyde was found to be -1,182 mV. For electron transfer to occur the 
potential of donor/acceptor must be close enough and the reduction potential values 
suggest that the reduced FAD in UGM may not be a strong enough reducing agent for the 
oxocarbeniuim ion to generate galactosyl radical.  
In summary, three different mechanisms have been proposed for the UGM 
reaction and a major difference among them is the mechanism of formation of the FAD-
galactosyl adduct. Evidence for and against the proposed mechanisms further complicates 
the interpretation of this unique enzymatic reaction. Further biochemical investigations 
are required to understand the precise mechanism of UGM reaction, which is beyond the 
scope of the current study.  
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1.4 Structure of UGM 
The crystal structure of ecUGM was the first in this class of enzyme solved 
(Sanders et al, 2001). Subsequently, crystal structures of kpUGM and mtUGM were 
determined (Beis et al, 2005). UGM is a homodimer and belongs to the α/β class of 
protein. Each monomer of UGM has three distinct domains (Figure 1-7). Domain 1 is a 
FAD binding region that is made of αβα Rossmann fold, a unique secondary structural 
element/motif found in nucleotide binding proteins. Most of the interactions of FAD are 
A       B 
 
 
 
 
 
 
Figure 1-7 Structure of ecUGM. A) Ribbon diagram representation of the dimer, 
monomer A (blue) and monomer B (green). FAD represented as sticks. B) Overlay of 
monomer A and monomer B to highlight the differences in the mobile loop conformation. 
Note the closed and open conformation of the mobile loop in monomer A and monomer 
B respectively.  
 
through hydrogen bond formation with conserved side chains. The two methyl groups of 
the isoalloxazine ring in FAD are stabilized by hydrophobic contacts with the conserved 
tyrosines (for example Tyr314 in kpUGM) The FAD binding domain (αβα Rossmann 
fold) is commonly found in other nucleotide binding proteins, but domain 2 and 3 were 
considered as unique for a FAD binding protein. Later, folds similar to domain 1 and 2 
were identified in a FAD binding protein, known as protoporphyrinogen oxidase (PPO), 
 
Domain I: 
FAD binding 
Domain III: 
β-sheets
Domain II: 
α helices
Loop 1
Loop 2
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although, the function of UGM and PPO are unrelated (Corradi et al, 2006). Domain 2 is 
a α-helical bundle made of five α-helices with two mobile loops that can exist in an open 
and closed conformation (Sanders et al, 2001). Domain 3 is an anti-parallel β-sheet made 
of six β-strands. The majority of the active site residues are located in domain 2 and 
domain 3 (Chad et al, 2007; Sanders et al, 2001).  The overall architecture of monomer A 
and monomer B is similar (rmsd of 1.4 Å for all equivalent Cα atoms), but differences in 
the mobile loop conformation were observed. In monomer A, the mobile loops exist in a 
closed conformation, while in monomer B an open conformation was observed for the 
mobile loop (Sanders et al, 2001). The overall structures of ecUGM, kpUGM and 
mtUGM similar and the monomers of ecUGM, kpUGM and mtUGM could be 
superposed with an rmsd of 1.0 Å (ecUGM and kpUGM), 1.2 Å  (ecUGM and mtUGM), 
1.2 Å (kpUGM and mtUGM) for all equivalent Cα atoms. The sequence identity between 
ecUGM and kpUGM, ecUGM and mtUGM, kpUGM and mtUGM are 39 %, 42 % and 
37 % respectively.  
 1.5 Conformation of oxidized and reduced FAD     
Crystal structures of ecUGM and mtUGM were determined with oxidized FAD. 
kpUGM structure was solved with both oxidized and reduced FAD (Beis et al, 2005). In 
oxidized UGM structures, the isoalloxazine ring of FAD is planar and N5 atom is sp2 
hybridized (Figure 1-5). In reduced structure (FADH-) the isoalloxazine ring is slightly 
puckered and N5 is sp3 hybridized and it is known as a butterfly or bent conformation 
(Figures 1-5 and 1-8). In FADH- the puckering of isoalloxazine ring can occur in two 
ways, namely, re-face or si-face. In FADH2 containing structures, like thioredoxin 
reductase (PDB code: 1C10), polyamine oxidase (PDB code: 1B37), and cholesterol 
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oxidase (PDB code: 1COY) re-face bending for isoalloxazine ring was observed (Binda 
et al, 1999; Haynes et al, 2002; Lennon et al, 1999; Yue et al, 1999). In reduced kpUGM 
structure, isoalloxazine ring of FADH- is puckered in a si conformation. The N5 atom in  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-8 Structure of reduced kpUGM. Ribbon diagram representation (stereoview) of 
the reduced kpUGM (PDB code 2BI8). The N5 of FADH- (represented as sticks) is 
pointing towards the protein (si face). 
 
the si conformation is not facing the substrate binding cleft, but point towards the protein 
(Figure 1-8). The si-face bending was also observed for the isoalloxazine ring of FMN in 
nitroreductase from Enterobacter cloacae (PDB code: 1KQD). The si conformation for 
FADH- in kpUGM causes significant difficulty for covalent catalysis to occur as this may 
cause steric clashes between the sugar moiety and active site residues. In order to avoid 
steric clashes and form an FAD-galactosyl adduct, the protein would need to undergo 
significant conformational changes including the backbone structure. It has been 
proposed that reduced kpUGM may favor the si conformation over the re conformation 
and substrate binding may perturb the active site architecture to favor re conformation 
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over si conformation. Also, the energy barrier for the interconversion between re-face 
and si-face bending is only 4-5 kcal/mol (Moonen et al, 1984), which could be gained 
upon substrate binding.  
1.6 Role of active site residues 
The crystal structures of ecUGM, kpUGM, mtUGM together with the sequence 
alignment of various bacterial UGMs, revealed the conserved residues involved in FAD 
and substrate binding (Chad et al, 2007). The role of active site residues in ecUGM and 
kpUGM have been studied through site-directed mutagenesis (Chad et al, 2007; Sanders 
et al, 2001). The active site mutants of kpUGM and their kinetic parameters are shown in 
Table 1-1. It is evident that most of the mutations affect the enzyme activity. Most 
importantly, two conserved arginines are critical for activity. A pronounced effect on 
substrate binding was also observed on replacing the active site tryptophan (W160A in 
kpUGM). Modeling studies suggest that Trp184 is involved in stacking interactions with 
the uracil ring of the substrate and this is consistent with the results of the mutagenesis 
experiments.  The four active site tyrosines were found to be important for substrate 
binding, but, not critical for activity.  The two acidic residues, Asp351 and Glu301 are 
conserved in prokaryotic UGM, while in some homologs the residue that corresponds to 
Asp351 is an asparagine and the residue that corresponds to Glu301 is an aspartic acid 
(Chad et al, 2007). Mutation of these acidic residues affects binding and catalytic activity. 
It is possible that these acidic residues may be involved in stabilization of a positively 
charged intermediate formed during the reaction or act as hydrogen bond donor/acceptor 
for the substrate. The two active site arginines (Arg174 and Arg280) are absolutely 
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essential for UGM activity, replacement of either of the arginine residue results in a 
completely inactive enzyme. Arg174 is located on a mobile loop away from the active  
Table 1-1 Kinetic parameters for kpUGM active site mutants. 
Protein   Km (µM)  kcat (min-1)  kcat/Km 
WT   43 ± 6   330 ± 40  7.7 x 106 
E301A   205 ± 18  18 ± 2   8.8 x 104 
D351A  1002 ± 284  8 ± 2   8.0 x 103 
W160A           *2.53 x 106  n/a*   130 
R280A   ND   ND 
R174A   ND   ND 
Y185F   386 ± 92  78 ± 14  2.0 x 105 
Y155F   619 ± 117  217 ± 25  3.5 x 105  
Y349F   739 ± 63  103 ± 16  1.4 x 105 
Y314F   819 ± 182  313 ± 40  3.8 x 105 
 
*Km value calculated assuming the kcat would be similar to wild type 
ND (not determined) 
 
site and it is apparent that the flexibility of this loop could result in the movement of 
Arg174 towards the active site and stabilize the negatively charged phosphate groups of 
the substrate. Modeling studies support the movement of this flexible loop and the side 
chains of conserved arginine (Arg170 in ecUGM and Arg174 in kpUGM) make contacts 
with the phosphate groups (Chad et al, 2007; Yuan et al, 2008). Modeling studies also 
suggest that the β-phosphate group of UDP-Galp can be stabilized by the side chain of 
Arg280 (in kpUGM). Stabilization of the phosphate groups of the substrate by the two 
conserved arginines underline their functional role in UGM.  
1.7 Molecular simulations 
In order to understand the binding mode of substrate and mobile loop movement 
modeling studies (docking and molecular dynamics simulation) have been carried out on 
UGM (Chad et al, 2007; Yuan et al, 2008; Yuan et al, 2005). AutoDock (Goodsell et al, 
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1996) was used to model the substrate binding into the active site. Docking studies were 
performed using ecUGM, monomer A and B. The monomers of ecUGM differ in their 
structure with respect to mobile loop conformation. The mobile loops exist in a closed 
and open conformation in monomer A and monomer B respectively. The mobile loops in 
kpUGM and mtUGM exist in a more open conformation. The substrate binding pocket of 
ecUGM monomer A and B are slightly different due to the open and closed conformation 
of the mobile loop. The docked conformation of UDP-Galp in monomer A showed 
numerous interactions with the side chains of conserved active site residues. In this 
binding mode, the uracil ring of UDP-Galp is involved in pi-stacking interactions with 
Trp156 (ecUGM). The β-phosphate group of UDP-Galp was stabilized by the side chain 
of Arg278. The sugar moiety is in close proximity to the isoalloxazine ring of FAD (3.0 
Å from N5 of FAD to anomeric carbon of galactopyranose). The majority of interactions 
for UDP-Galp are from the UDP moiety which is surrounded by 15 residues. This is 
consistent with the results obtained from saturation transfer difference (STD) NMR 
experiments that showed strong signals for the protons of UDP as compared to the 
galactose moiety (Yuan et al, 2005). STD-NMR experiments were done for UDP and its 
signals were similar to the UDP portion of UDP-Galp. This suggests that uridine moiety 
play an important role in the binding of UDP-Galp to UGM.  
In monomer B, the docked conformation of UDP-Galp is significantly different 
from monomer A. In this binding mode, the sugar moiety is not located adjacent to the 
isoalloxazine of FAD. Also, the stacking interactions between the uracil ring of UDP-
Galp and Trp156 are not observed. However, the salt-bridge interactions between the 
Arg278 and the phosphate group of UDP-Galp in monomer B were similar to the one 
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observed in monomer A. Docking studies on UGM were helpful in predicting the binding 
mode of UDP-Galp and also underline the role of some active site residues. To account 
for the flexibility of the enzyme, especially the movement of mobile loops, molecular 
dynamics simulation (MDS) were performed on UGM. MDS is one of the modeling 
techniques that can be used to simulate the movement of atoms in a molecule on a time 
scale and analyze the changes in the structure for the given time period. MDS 
calculations on ecUGM (monomer B) with modeled UDP-Galp revealed the 
rearrangement of mobile loops, i.e., from open to closed conformation. Arg170 located in 
the mobile loop was found to interact with the phosphate group of UDP-Galp (Yuan et al, 
2008). Similar results from MDS studies were observed for kpUGM (Chad et al, 2007) 
and mtUGM (unpublished data). MDS studies corroborate the proposed mobile loop 
movement that occur upon substrate binding and is consistent with the mutagenesis 
studies of Arg174 of kpUGM (Chad et al, 2007).    
1.8 Enzyme kinetics and inhibition 
 
The work presented in this thesis includes enzyme kinetics and inhibition studies 
on UGM. Hence, an introduction to these two topics is given in this section. Enzymes are 
catalysts that enhance the rate (velocity) of a reaction without affecting the equilibrium of 
the reaction. In most cases, enzymes convert one chemical (substrate) into another 
(product). Some enzymes can bind to more than one substrate. Enzyme catalysts differ 
from chemical catalysts in many ways, for example, enzymes achieve remarkable rate 
enhancements, high degrees of specificity, diversity in the types of reaction catalyzed and 
tight regulation of catalysis by cellular metabolites (Kraut 1988).  The active site of an 
enzyme is defined as the location on the enzyme where catalysis takes place. The rates of 
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enzyme-catalyzed reaction can be decreased or increased by inhibitors or activators 
respectively. Enzyme kinetics is an important experimental tool to study the rates of 
enzyme-catalyzed reactions. The overall goal of enzyme kinetics is to measure, analyze 
and interpret the rate of enzyme-catalyzed reactions. Enzyme kinetics provides evidence 
about the enzyme mechanisms and is also helpful in defining the role of active site 
residues involved in substrate binding and catalysis.  
 
 
 
 
 
 
 
 
 
 
Figure 1-9 Effect of substrate concentration on the initial velocity of an enzyme-
catalyzed reaction. The substrate concentration at which Vo is half-maximal is Km, the 
Michaelis constant. 
 
The rate of enzyme catalyzed reaction is influenced by many parameters and one key 
factor is the substrate concentration [S]. The effect on Vo (initial velocity) by varying [S] 
at constant enzyme concentration is shown in Figure 1-9. At relatively low [S], Vo 
increases linearly with increase in [S]. However, at higher [S], Vo increases slowly and 
reaches a point beyond which there is insignificant changes in the Vo with increasing [S].   
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This flat region (plateau) of the graph is called the maximum velocity Vmax. The 
relationship between the substrate concentration and rate of enzyme catalyzed reaction 
can be expressed quantitatively using Michaelis-Menten equation (5-1). 
  
  Vmax [S]                               
         Vo =                                                          (5-1) 
                                             Km + [S] 
 
Km is the [S] at which Vo is one-half of Vmax. 
Km can also be defined by the expression,  
 Km = k2 + k-1 (5-2) 
                    
k1 
 
k1, k-1 and k2 are shown in equation 5-3 
                         k1              k2 
E + S       ES          E + P                         (5-3) 
          k
-1 
In equation 5-3, ES represents the enzyme-substrate complex and P represents the 
product. When  k2<<k-1, then Km reduces to k-1/k1, which is a dissociation constant (Kd) 
for the ES complex. Under these conditions Km can be considered as a measure of the 
affinity of the enzyme for the substrate. For a reaction with multiple steps after formation 
of the ES complex, then Km becomes a complex function of many rate constants. Km and 
kcat are the two widely used parameters in enzyme kinetics. kcat is a first-order rate 
constant with units of reciprocal time and is also known as the turn-over number. It is the 
number of substrate molecules converted to product in a given unit of time by a single 
enzyme molecule when the enzyme is saturated with the substrate. In order to compare 
the catalytic efficiency of different enzymes or different substrate towards an enzyme the 
factor kcat/Km is generally used.  
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Inhibitors are molecules that bind to a specific site of an enzyme and prevent 
enzyme catalysis. The inhibitor may bind reversibly or irreversibly to the enzyme. The 
structure of the inhibitor may or may not resemble the substrate molecule, when inhibitor 
structure is similar to substrate then it is called as substrate mimic or substrate analog. 
Substrate analogs are often used as probes to investigate enzyme mechanisms (John, 
2007).  
Reversible inhibitors show three different types of inhibition mode, namely, 
competitive, uncompetitive and noncompetitive (Figure 1-10). Competitive inhibitors 
compete for the same site as the substrate and they bind only to free enzyme. The 
inhibitory activity of a competitive inhibitor can be altered by substrate concentration, for 
example, increasing the substrate concentration can displace the inhibitor from the active 
site and decrease the amount of inhibitor binding to the same site. If an inhibitor binds 
only to the ES complex, then it is termed as uncompetitive inhibition. In uncompetitive 
mode high concentration of substrate increase the concentration of ES and this will 
increase the amount of inhibitor binding to it. In case of noncompetitive inhibition, the 
inhibitor binds to either the free enzyme or the ES complex. Inhibitor binding does not 
affect the binding of substrate, i.e, substrate can still bind to the enzyme. The enzyme is 
inhibited by the inhibitor irrespective of the presence or absence of substrate. This mode 
of inhibition is also called as “mixed” inhibition and such inhibitors are termed as mixed 
inhibitors.  The uncompetitive and noncompetitive modes of inhibition are often observed 
with enzymes that catalyze the reaction between two or more substrates. Most 
importantly, uncompetitive and noncompetitive inhibitors bind to a site different from the 
substrate binding site. The three modes of inhibition can be determined by various  
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Figure 1-10 Schematic representation of the three types of reversible inhibition (E, 
enzyme; S, substrate; I, inhibitor).  A) Competitive inhibitors bind to the active site of the 
enzyme B) Uncompetitive inhibitors bind at a distinct site to that of the substrate, but, 
bind only to the ES complex. C) Noncompetitive inhibitors bind at distinct site, but, can 
bind to E or the ES complex.  
  
graphical plots (for example, Lineweaver-Burk plot) of the kinetic analysis carried out in 
the presence of inhibitor. The pattern of the lines from this plot can suggest the type of 
inhibition observed with the inhibitor. 
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1.9 Inhibitors of UGM 
As discussed previously, UGM is a potential target for antibacterial drug 
development. Many research groups have designed, synthesized and evaluated diverse 
chemical scaffolds as inhibitors of UGM (Peltier et al, 2008; Richards & Lowary, 2009). 
Only a few of them showed promising inhibitory activity towards UGM. The inhibitors 
of UGM can be classified into distinct structural classes and for better clarity each class 
will be discussed separately.   
1.9.1 Sugar-based derivatives 
 A number of sugar-derivatives have been synthesized as inhibitors of UGM 
(Figure 1-11). Among them are the imino-sugars (Desvergnes et al, 2007; Ghavami et al, 
2004; Veerapen et al, 2004), alditolaminophosphonates (Pan et al, 2007)  and pyrrolidine 
analogs (Lee et al, 1997) (Figure 1-11). The sugar-based derivatives showed no inhibition 
or poor inhibitory activity.  
 
A         B   C           D 
 
 
 
 
 
Figure 1-11 UGM inhibitors based on sugar derivatives. A) and B) iminosugars C) 
pyrrolidine analog D) alditolaminophosphonates.  
 
The sugar derivatives may occupy only the sugar binding region of the active in 
UGM and do not make contacts with the residues of the UDP binding region. Modeling 
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suggests that the residues near the UDP region contribute to the binding of UDP-Galp 
and absence of this moiety in these molecules may account for their poor inhibition.  
1.9.2. Substrate analogs 
 Inhibitors based on substrate (UDP-Galp and UDP-Galf) have been synthesized as 
inhibitors of UGM (Figure 1-12). Notable among these substrate analogs are the 
fluorinated analogs of UDP-Galp and UDP-Galf. The 2-fluoro and 3-fluoro analogs of 
UDP-Galp were found to be poor substrates of UGM, but neither of them were tested for 
their inhibitory activity against UGM (Barlow & Blanchard, 2000). The 4-fluoro analog 
of UDP-Galp was shown to inhibit (~ 50 % at 166 µM) the conversion of UDP-Galf to 
UDP-Galp (Burton et al, 1997). 2- and 3-fluoro analogs of UDP-Galf were synthesized 
and evaluated for activity against UGM. These analogs are also poor substrates for UGM, 
but are not inhibitors (Zhang & Liu 2001).  
Sugar nucleotide mimetics such as iminogalactofuranose-UMP conjugates were 
synthesized as inhibitors of UGM, but the biological activity of these compounds were 
not reported (Liautard et al, 2006). A peptide analog of UDP-Galf based on 
iminogalactofuranose template has been designed and synthesized as inhibitor of UGM 
(Lee et al, 1999), although the inhibitory activity for this compound is not known. 
Phosphonate analogs of UDP-Galp and UDP-Galf were synthesized as inhibitors for 
UGM (Caravano & Vincent, 2009). These analogs were evaluated for activity (towards 
ecUGM) under non-reducing and reducing conditions (See section 5.3.1). The 
phosphonate analog of UDP-Galp showed 36 % inhibition at 1 mM under non-reducing 
condition, but under reducing conditions < 10 % inhibition was observed. UGM is active 
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only when it is reduced and it is more appropriate to perform inhibition studies under 
reducing condition to evaluate their potency. The substrate (UDP-Galf) concentration in  
A        B 
 
 
 
 
 
C          D 
 
 
 
 
E 
 
 
 
 
Figure 1-12 Substrate analogs as UGM inhibitors. A) and B) Fluoro analogs of UDP-
Galp C) and D) Fluoro analogs of UDP-Galf  E) iminogalactofuranose-UMP conjugate. 
 
their assay was set to 1 mM, while the Km for ecUGM is only 27 µM  (Caravano & 
Vincent, 2009). The higher concentration of substrate used in the assay may affect the 
proper evaluation of inhibitors (See section 5.3.1). 
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1.9.3. Thiazolidinone derivatives 
Inhibitors based on 5-arylidene-2-thioxo-4-thiazolidinone (ATT) core were 
identified in a high throughput screening (HTS) against kpUGM (Carlson et al, 2006). 
Based on the ATT core various analogs have been synthesized and evaluated for 
inhibitory activity against kpUGM and mtUGM. One compound (Figure 1-13) in this 
series showed promising activity towards kpUGM (IC50  = 1.6 µM), but, its activity 
towards mtUGM is 40-fold lower (IC50 65 µM). These compounds showed selectivity 
 
 
 
 
Figure 1-13 UGM inhibitor based on 5-arylidene-2-thioxo-4-thiazolidinone scaffold. 
towards kpUGM as compared to mtUGM. It is possible that subtle differences in the 
active site architecture between mtUGM and kpUGM may account for the differences in 
activity. Unfortunately, these compounds have the possibility of undergoing covalent 
modification (due to the conjugated system) by reacting with nucleophiles like thiols and 
this is an undesirable property in a lead like molecule for further development. 
 1.9.4. Nitrofuranyl amides 
Antibacterial agents based on a nitrofuran scaffold are well known in the 
pharmaceutical market, for example, nitrofurantoin used in the treatment of urinary tract 
infections. Also, the antimicrobial agent metronidazole has structural similarity to a 
nitrofuran scaffold. Based on this precedent, a library of compounds based on 
nitrofuranyl amides were designed, synthesized and evaluated for their inhibitory activity 
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towards mtUGM (Figure 1-14) (Tangallapally et al, 2004). Compounds from this series 
showed moderate activity in in-vitro assays. The MIC activities of these compounds are 
comparable to the MIC values of front-line anti-tuberculosis agents, like, isoniazid and 
ethambutol.  The moderate IC50 values of these compounds do not correlate with the 
excellent MIC values and this suggests that targets other than UGM may account for their 
potent MIC activities. 
 
 
 
Figure 1-14 UGM inhibitor based on nitrofuran core. 
1.9.5. Uridine derivatives 
A microtiter plate-based assay has been designed to identify inhibitors of UGM 
(Figure 1-15) (Scherman et al, 2003). The assay is based on the formation of tritiated 
formaldehyde from UDP-Galf and not from UDP-Galp in the presence of periodate. This 
assay was successfully used to screen a uridine-based chemical library and a potential hit 
molecule was identified (320KAW73). The approximate IC50 value of 320KAW73 was 
found to be 6.0 µM, but the inhibitor was found to be inactive in a cell-based assay.  
 
 
 
 
 
Figure 1-15 Uridine based inhibitor identified through microtiter plate-based assay. 
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1.10 Research Objectives  
The unliganded UGM structures (ecUGM, kpUGM and mtUGM) provided 
insights onto the UGM structure, FAD binding and also the role of few active site 
residues. The crystal structure of UGM bound to substrate was not available or reported 
at the time of initiating this study. One of the objectives of the current study is to 
determine the structure of UGM in complex with the substrate (UDP-Galp) by X-ray 
crystallography.  
UGM:substrate complex structures 
The UGM:substrate complex structure would help us to understand the active site 
interactions and the role of each amino acid at a molecular level. UGM:substrate complex 
structures would reveal the conformational changes (mobile loop rearrangements) that 
occur upon substrate binding and its effect on interactions with the substrate. Also, 
UGM:substrate complex structures may provide a platform for structure-assisted design 
of inhibitors for UGM. The structures of oxidized and reduced UGM:substrate complexes 
would reveal the structural differences between them and the role of FAD. In addition, I 
also address the question of how UMP, UDP, and UDP-glucose bind to UGM.  
Inhibition studies on UGM 
Inhibitors of UGM based on various chemical scaffolds have been reported, but 
most of them have only moderate inhibitory activity. Another objective of this thesis is to 
identify UGM inhibitors that could act as antibacterial agents. Both ligand and structure-
based approaches were used to identify inhibitors for UGM.  
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CHAPTER 2 
Outline of Protein crystallography 
2.0 Introduction to protein crystallography 
 
The biological function of a protein molecule and its three dimensional structure 
are closely related, i.e., structure determines the function. Protein structures can be 
determined by NMR or X-ray crystallography (Wlodawer et al, 2008). Scientific and 
technological advances in NMR and X-ray crystallography have led to the rapid 
determination of three dimensional structures of various macromolecules. The structures 
reported here are determined by X-ray crystallography and this chapter is an overview of 
the various steps involved in protein crystallography. Protein crystallography essentially 
involves four major steps that include: 1) Crystallization, 2) Crystal diffraction (Data 
collection and processing), 3) Phase determination and 4) Refinement and model-
building.   
2.1 Crystallization of proteins 
Crystal growth is a phase transition phenomena to form solid particles by 
aggregation of molecules in the solution (McPherson, 2004; McPherson, 2009). The 
process of aggregation does not occur in unsaturated or saturated solutions. In the case of 
undersaturated systems, the concentration of the solute is below its solubility limit, 
however, when the concentration of the solute reaches its solubility limit the system is 
saturated. In a saturated system, equilibrium is established between the solid and the 
solution state, but crystals cannot grow under these conditions. A supersaturated solution 
represents a system where the concentration of the solute exceeds its solubility limit, i.e, 
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more solute molecules are present in solution than its solubility limit and such a system is 
not in equilibrium. Hence, a supersaturated system is essential for crystal growth. 
A plot of precipitant concentration vs protein concentration (phase diagram) 
reveals different zones that are favorable and unfavorable for crystal growth (Figure 2-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
Figure 2-1 Schematic illustration of protein crystallization phase diagram.  
 
 The process of crystal growth can be divided into three stages, namely, nucleation, 
crystal growth and cessation of growth. Unsaturated and saturated systems are 
unfavorable zones in the phase diagram that do not result in crystal growth. When the 
system is supersaturated then spontaneous formation of critical nuclei (labile zone) 
occurs and this triggers the aggregation of molecules leading to the formation of crystals. 
The metastable zone in the phase diagram represents another supersaturated system ideal 
for crystal growth, although nuclei formation does not occur in this region. The labile 
region (precipitation zone) not only forms crystal nuclei, but amorphous precipitate as 
well and this is a major problem in protein crystallization. In order to form protein 
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crystals, one has to bring the system to the labile zone to form few nuclei which will 
continue to grow in the metastable zone without formation of any new nuclei and 
precipitation. The termination or cessation of crystal growth could be due to drop in 
supersaturation levels, crystal surface defects and impurity poisoning that inhibits the 
crystal growth.  
Proteins can be crystallized by different methods (Table 2-1) and all of them have 
a common theme of bringing the protein solution to a supersaturated state, which leads to 
nucleation and crystal growth. Among the various methods for crystallization, vapor 
diffusion methods are more popular than any other approach.  
Table 2-1 Various methods for protein crystallization. 
 
 
 
 
 
 
 
Vapor diffusion methods are of two types, sitting drop and hanging drop. If the 
drop (protein and precipitant solution) is supported by some surface, it is called sitting 
drop, and if the drop is suspended from some surface it is called hanging drop (Figure 1-
10). The principle in both methods is essentially the same. The protein/precipitant 
solution is allowed to equilibrate in a closed system and this will increase the precipitant 
and protein concentration (in the drop) driving the system to supersaturation and crystal 
formation.  
S. No Method 
1 Bulk crystallization 
2 Batch method 
3 Dialysis 
4 Seeding 
5 Free interface diffusion 
6 Vapor diffusion 
7 Temperature induced 
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Microbatch crystallization is a variant of batch crystallization carried out under oil 
(Chayen, 1997; Chayen, 1998). The protein solution and crystallization reagent are 
pipetted under a small layer of oil (Figure 2-2). The oil layer acts as a barrier and hence 
there is little or no diffusion of water through the oil. The major advantage of batch or 
microbatch method is all the reagents involved in the crystallization are present at a 
specific concentration to create a supersaturated system. Also, in batch experiments  
 A                                      B                            C 
 
 
 
 
Figure 2-2 Schematic representation of the set up for vapor diffusion and microbatch 
crystallization. A) Hanging drop B) Sitting drop C) Microbatch method. 
 
the concentration of the protein and the crystallization reagent in the drop do not vary 
significantly over the period of time. Microbatch methods are well suited for automation 
and require less volume of protein and crystallization reagents. 
2.2 Crystallization of protein-ligand complexes 
Crystals of protein-ligand complexes can be formed by two different approaches, 
namely, cocrystallization and soaking (Hassell et al, 2007). A major difference between 
them is the time at which ligand is incorporated into the protein. In cocrystallization, the 
ligand is added to the protein solution to form protein-ligand complex and then crystal 
trials are carried out using this protein-ligand solution. Soaking methods rely on 
preformed protein crystals and the ligand is introduced by soaking the crystal into a 
Dispensing tip
Low density oil
Crystallization plate
Crystallization drop
Protein drop
Crystallization solution
Protein drop
Crystallization solution
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crystallization reagent that contains the ligand at appropriate concentration. A number of 
parameters affect the incorporation of ligand by cocrystallization and soaking as well. For 
example, cocrystallization is sensitive to ligand concentration and solubility, protein 
concentration and temperature. The ligand solubility is a major factor in forming protein-
ligand complexes. To increase the chances of forming protein-ligand complexes, higher 
concentration of ligand is required without any precipitation when mixed with the protein 
solution. In general, the ligand concentration that is required to form protein-ligand 
complex is 10 times more than the dissociation constant (Kd) of the ligand to achieve full 
occupancy. The solubility of ligand may vary with respect to temperature; thus protein-
ligand complex formation by cocrystallization can be carried out at various temperatures. 
The addition of a ligand to a concentrated protein solution may result in the precipitation 
of protein due to the limited solubility of the ligand. One way to overcome this issue is to 
mix the diluted protein sample and dilute ligand solution, for example crystals of kinase 4 
were formed by diluting the protein to 1 mg/ml and diluted ligand added (at 1:3) to form 
a stable complex and found to give well diffracting crystals.   
Soaking is a common method of choice to obtain protein-ligand complex crystals 
(Hassell et al, 2007). A number of factors need to be taken into consideration in forming 
protein-ligand crystals by soaking. Most important parameter is the stability of protein 
crystals. Crystals should be stable and withstand the soaking conditions. Conformational 
changes that occur upon soaking may result in cracking of crystals and eventually 
dissolve them. The conformational changes observed with soaking may not represent the 
true conformational state of the protein and could be validated with crystals obtained by 
cocrystallization experiments. The soaking time and the concentration of the ligand needs 
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to be optimized to achieve full occupancy. It has been shown that addition of certain 
compounds, known as additives, stabilize the crystals during the soaking process (Hassell 
et al, 2007). Use of additives is also common in the cocrystallization method. Ligands 
can also be soaked into preformed protein-ligand complex crystals and this process is 
known as ligand exchange. The success of this method depends on the affinity (Kd) of the 
second ligand to successfully displace the preoccupied ligand.   
2.3 Crystal harvesting and mounting  
Crystals from the crystallization drop need to be isolated (harvested) and mounted 
on a goniometer for diffraction experiments (Pflugrath, 2004). Crystals are looped from 
the drop and placed in the crystallization reagent that contains a chemical or compound 
known as cryoprotectant. When protein crystals are exposed to X-rays, free radicals are 
generated that can damage the protein crystals. The damage by free radicals can be 
minimized by collecting the data at cryogenic temperatures (-196 oC) by using a stream 
of nitrogen gas. This is known as cryomounting. Under these conditions ice crystals are 
formed that are detrimental to protein crystals.  The presence of a cryoprotectant in the 
crystallization reagent favors the formation of glassy ice over ice crystals. A wide range 
of compounds are available for cryoprotection, such as glycerol, ethylene glycol, sugars, 
PEGs etc. Crystals can be mounted using a small loop made from a thin fiber, but 
different types of loops are are available to meet the specific requirements (Hampton 
Research Inc). 
2.4 Why do we use X-rays?  
If one wishes to determine an image of a protein molecule at an atomic level, then 
a light source (electromagnetic wave) of suitable wavelength must be used. The atomic 
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structure of a molecule can be obtained if the wavelength of the electromagnetic radiation 
is 1-2 Å (interatomic distance in protein molecules). In the electromagnetic spectrum, X-
rays match this criteria and their wavelengths range from 2.3 - 0.6 Å (5-25 KeV). Hence, 
X-rays are used to study the three dimensional structures of protein molecules that are 
packed in a crystal (Rhodes 2006; Rupp 2010).  
X-rays that are useful for crystallography can be produced by bombarding a metal 
target (Molybdenum or Copper) with electrons. When high-energy electrons strike the 
metal atom it displaces an electron from the lower orbital and then an electron from a 
higher orbital drop into the vacant orbital, releasing X-ray photons of particular energies, 
known as characteristic radiation. There are three common X-ray sources, namely, X-ray 
tubes, rotating anode tubes and particle storage rings (synchrotron radiation). In case of 
X-ray tubes heat dissipation from the anode by the circulating water affects the output. A 
higher X-ray output can be obtained by using rotating anode tubes, in which the target 
metals rotate rapidly and this arrangement helps in heat dissipation by spreading the 
bombardment over the large piece of metal. In particle storage rings, charged bodies like 
electrons emit energy (synchrotron radiation) when forced into a curved motion and the 
energy emitted include X-rays. They are the most powerful X-ray sources.  
2.5 Crystals, diffraction and symmetry 
        Cystals are regular three dimensional arrays of atoms, groups, molecules or 
molecular assemblies (Rhodes 2006; Rupp 2010). W. L. Bragg proposed that diffraction 
could be considered as a reflection from a set of equivalent parallel planes of atoms 
(electrons) in the crystals. Constructive interference (measurable reflections) from the 
 36 
scattered rays will take place if the path difference between these rays is equivalent to an 
integral number of wavelength and this is known as Bragg’s law (equation 2-1). 
nλ = 2d sin θ                (2-1) 
n is an integer, λ = wavelength of the X-rays,  d = interplanar spacing between the planes 
and θ = angle between the incident ray and scattering planes  
 
        The reflections or diffraction pattern of a lattice is also a lattice and its dimensions 
have reciprocal relationship to the real lattice. This arrangement of lattice points in 
reciprocal space is called the reciprocal lattice. The sphere of reflection or Ewald’s sphere 
is an imaginary geometric construction that tells us how the reciprocal lattice point must 
be arranged with respect to the X-ray beam in order to satisfy Bragg’s law and produce a 
reflection from the crystal. Considering a sphere with radius 1/λ  (wavelength in 
reciprocal space) from the center of the crystal and any reciprocal lattice point in contact 
with the surface of the sphere will satisfy Bragg’s law in reciprocal space and reflection 
occurs. Hence, during data collection it is necessary to rotate the crystal so that as many 
as possible reciprocal points come in contact with the surface of the sphere of reflection 
resulting in measurable reflections.  
        Individual atoms from a protein molecule can diffract X-rays, albeit too weakly to 
measure. A crystal can diffract X-rays strongly as compared to a molecule, because a 
crystal is composed of many identical units called unit cells. Each unit cell is composed 
of the same number of molecules packed in identical orientation. This arrangement of 
molecules in each unit cell can diffract X-rays in unison and results in the amplification 
of diffraction by each atom in a measurable form known as spots or reflections. The 
diffraction pattern observed for a protein crystal is characteristic and depends on the 
crystal symmetry. In order to determine the structure of a protein molecule, it is important 
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to know the symmetry information of the crystal, for example, the unit cell symmetry 
guide us to collect only the unique reflections and greatly reduce the magnitude of data 
collection. Based on the lattice symmetry it is possible to have seven crystal systems. 
Bravais showed that there are only 14 possible ways that identical lattice points can be 
arranged in space with the condition that each point has same number of neighbors at the 
same distances and in the same directions. These are called the 14 Bravais lattices 
(Rhodes 2006).  
        A symmetry operation is an event of converting one object into another identical 
object. Symmetry operations can take place about a point, a line or a plane. The point, 
line or plane about which symmetry operations are done is defined as a symmetry 
element.  The combination non-translational symmetry elements passing through a single 
point (geometric centre of the crystal) lead to 32 crystal classes or point groups and 
crystals belong to any one these crystal classes. When symmetry operations are applied to 
points arranged periodically on a crystal lattice, the result is a space group. Two 
additional symmetry elements with translation are possible, namely, screw axes and glide 
planes. The combination of the 14 Bravais lattices with the 32 crystal classes and the 
possibility of translational symmetry (screw axes and glide planes) result in 230 unique 
crystallographic space groups. Biological macromolecules such as proteins (composed of 
only L-amino acids) crystallize in space groups that do not possess either inversion 
symmetry or symmetry plane (symmetry elements that change the hand of the molecule) 
and hence only 65 distinct space groups are possible for proteins. In addition to the unit 
cell symmetry, the diffraction pattern has a symmetry element called centre of symmetry 
or point of inversion at the origin. Friedel’s law states that the intensity of reflections that 
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comes from opposite sides of the same set of planes are identical (equivalence of Ihkl and 
I
-h-k-l). This additional symmetry in the reciprocal lattice allows further reduction in the 
total angle of data collection. An examination of diffraction pattern of a crystal may 
reveal that some reflections are missing (intensity of zero) and these missing reflections 
are due to certain symmetry elements present in the crystal. The reflections that are 
missing along the specific axis or planes are known as systematic absences. Systematic 
absences can assist in the determination of possible space group by looking at few sets of 
reflections.  
2.6 Data collection  
 
The data collection process involves the exposure of a crystal to X-rays and 
recording the diffraction pattern (the images) on a detector (Dauter, 1999). It is necessary 
to collect a few images to determine the crystal symmetry, unit cell dimensions, crystal 
orientation and resolution limit. This prescreening is essential to devise the strategy for 
data collection, which will maximize the completeness and the resolution of the dataset. 
The most common method of data collection in protein crystallography is the rotation or 
oscillation method. In the oscillation method, the crystal is rotated around a single axis in 
small increments, (0.1 to 1.5o) and diffraction images are recorded for each of these small 
angles of rotation. The angle of rotation required to collect a complete data set depends 
on the crystal symmetry.  The first few snapshots will give an indication on the extent to 
which the crystals diffract (resolution), the optimal exposure time, incremental angle, 
data anisotropy, the presence of ice rings, mosaicity, spot separation and sharpness of 
spots.   
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2.7 Data processing 
Data processing involves three distinct steps: 
1. Determination of the crystal cell parameters, space group and orientation. 
2. Integration of the images with simultaneous refinement of crystal, beam and detector 
parameters (Leslie, 2006). 
3. Data reduction to place all data on a common scale. Multiple observations are merged 
to give a unique dataset and outliers rejected. Intensities are reduced to structure factor 
amplitudes. 
The step 1 involves the determination of the crystal unit cell dimensions and 
identifying the space group symmetry of the crystal (Kabsch, 2010a; Rossmann & van 
Beek, 1999). This process is known as indexing. Most of the indexing methods are based 
on the Fourier analysis of a subset of spot positions of one or more images. In step 2, the 
position of reflection in each image is predicted and the intensity value with estimated 
error for each observation of reflection is carried out by integration of the diffraction spot 
(signal) and subtracting it from the X-ray background (noise).  In step 3, the intensities of 
reflections on each image are put on a common scale (scaling). This is necessary to 
account for the variations of the source intensity (e.g. beam decay at a synchrotron 
source), radiation damage and some absorption effects. Polarization and Lorentz 
correction factors are applied to account for these variations to put the data on a common 
scale. Once the data is scaled, multiple observations of the same reflections can be 
merged/reduced to a weighted mean intensity and standard deviation. At this stage of data 
processing various statistics are calculated to assess the data quality, such as Rsym, 
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completeness of data, signal-noise ratio [I/σ(I)] etc. Rsym shows the agreement between 
the symmetry related reflections between various images. The lower the Rsym value 
(overall and high resolution shell) the better the data quality. The final step in the data 
processing is to convert the intensity data to structure-factor amplitude. The structure-
factor has all the information (e.g., intensity of reflection) except the phase angle, the 
most critical data required to solve the protein structure.  
2.8 Protein structure determination: The Phase problem 
The aim of a protein crystallography experiment is to obtain the image of unit cell 
contents in the form of an electron density map (Rhodes 2006; Rupp 2010). The electron 
density map can be computed from intensities (from structure factors) and the phase 
angles of reflections using equation 2-2.       
    1 
ρ(x,y,z) =       ∑∑∑ |Fhkl| e-2pii(hx+ky+lz-α’hkl)                                (2-2) 
         V      h k l 
                    
In equation 2-2, ρ(x,y,z) is the electron density, F(h, k, l) represent the structure factor 
amplitudes and αhkl, the phases. In X-ray crystallographic experiments, we can measure 
the intensities and the wavelength of diffracted rays, but, the phase angle information of 
the diffracted beam cannot be measured and this is known as the phase problem in 
protein crystallography. The phase information required to compute the electron density 
can be derived by various methods. The phase problem can be solved by using a protein 
structure that is similar to the unknown structure (sequence identity ≥ 30 %) and this is 
known as molecular replacement method (MR). Alternatively, the phases can be derived 
experimentally by incorporating heavy-atoms into the protein molecule or protein crystal 
and changes in the intensity pattern due to the heavy atom incorporation can be used to 
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solve the phase problem. The structures reported here were determined by the MR 
method and it will be discussed in greater detail. 
2.9 Molecular replacement (MR)  
       Nearly three-quarters of structures deposited in the protein data bank (PDB) are 
solved by the MR method (Evans & McCoy, 2008; Rossmann, 2001). MR is helpful if 
the unknown protein structure is similar to a known structure and has ≥ 30 % sequence 
identity (Barton, 2008). The underlying assumption in MR is that the unknown protein 
structure will be similar to that of the known protein structure. MR avoids the time 
consuming process of heavy atom derivative preparation for solving the phase problem 
by isomorphous replacement or anomalous dispersion methods. Also, MR will be the 
method of choice for solving protein-ligand complexes if the structure of the unliganded 
protein is known.   
      In MR, the known protein structure that is used to calculate the initial phase of the 
unknown structure is called the phasing model. The phasing model has to be placed into 
the unit cell of the unknown protein and then used to estimate the initial phases for the 
properly positioned molecule. Placing the phasing model in the unit cell of the unknown 
protein in the right orientation and location is an important task in the MR method. The 
search procedure involves six variables, 3 rotation angles (Eulerian angles) for orientation 
and 3 translational parameters to find the position. In theory, it is possible to conduct all 
combinations of orientations and locations and compare the calculated amplitudes with 
the observed amplitudes obtained from the intensity data of the unknown protein.  This 
complexity can be reduced by separating the search process for best orientation from the 
search for the translation or best position. A Patterson map, a vector map, is used to find 
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the best orientation and position of the search model within the unit cell of unknown 
protein. To find the best orientation, the rotation function uses intramolecular vector 
maps (self-Patterson peaks), as they depend only on the orientation and not on its position 
in the unit cell.  If the model is properly oriented within the unit cell of the unknown 
protein then the Patterson map for the model and the unknown protein will be very 
similar. If the best orientation is found, then the particular solution can be used in the 
search for the best location/position of the model (translation). To find the best position, 
the translation function uses intermolecular vector maps (cross-Patterson vectors) as they 
depend on the position of the unit cell. A comparison of the Patterson maps between the 
model and that of the unknown protein would indicate the best position. If a best match is 
observed for a particular orientation and position, then the computed phases serve as the 
starting phases for the structure determination of the unknown protein. The search 
process is monitored by using R-factor (Equation 2-3), a parameter that compares the 
expected structure-factor amplitudes from the solution and the actual structure-factor 
amplitudes obtained from the intensity data of the unknown protein.  
 
                               (2-3) 
 
In general, R-values of 0.3-0.4 considered adequate as initial estimates of phases. 
2.10 Refinement, model building, validation and deposition 
Refinement is an iterative process of improving the model to agree with the 
experimental data, and the process of improvement is indicated by various statistics 
(Tronrud, 2004). The atomic positions, occupancies and temperature factors are the 
∑ Fobs - Fcalc
∑ Fobs
R =
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parameters taken into consideration for comparing the calculated structure factor 
amplitudes and observed structure factor amplitudes. During the process of refinement 
additional constraints (fixed value for a parameter) and restraints (values specified within 
the range) are applied to achieve a near global minimum (better agreement between the 
calculated and experimental structure factor amplitudes). In addition, molecular 
mechanics based refinement such as molecular dynamics and simulated annealing can be 
used to find the lowest energy conformation and this should agree with the observed 
diffraction data. During the iterative process of refinement, the observed and calculated 
structure-factor amplitudes converge and improve the quality of the model. The most 
widely used measure of convergence is the residual index or R-factor. An initial model 
with an R-factor of 0.4 is promising and is likely to improve with the refinement process. 
Another statistical parameter that is used to indicate the quality and improvement of 
model is the free R-factor or Rfree, and this is computed using small set of randomly 
chosen reflections (~ 5 %) that are not used during the refinement process. This is a 
cross-validation method or quality control process to assess the agreement between the 
calculated (from the model) and observed data. Rfree measures how the current model 
predicts a subset of measured reflections not included in the refinement, and R-factor 
measures how well the current model predicts the entire data set that produced the model. 
In addition, proper care must be taken that the model obeys the chemical rules (expected 
bond angle and bond lengths), stereochemistry (no inverted centers of chirality) and 
conformational criteria, such as, planarity of peptide bond, trans- conformation of non-
proline peptide bonds (except cis-proline), backbone conformational angles, Φ (Phi, N-
Cα) and Ψ (Psi, Cα-C) are within the allowed regions by interpreting Ramachandran plots 
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(sterically allowed conformations for certain Φ, Ψ values) and the side chains exist in 
stable staggered conformations. The final model is validated through the PDB (Protein 
Data Bank) or Molprobity servers before deposition (Berman et al 2000; Davis et al 
2004). After validation the model can be deposited in the PDB and each entry in the PDB 
is assigned a unique four letter code known as PDB accession code.  
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CHAPTER 3 
Materials and Methods 
3.0 Primers for PCR 
1. drUGM N372D mutant 
Forward 5’ -  CTA CCG CTA CTA CGA CAT GGA CCA GGT GG -  3’ 
Reverse 3’ - CCA CCT GGT CCA TGT CGT AGT AGC GGT AG -   5’ 
 
2. kpUGM D351N 
 
Forward 5’ - CCT ACC GTT ACC TTA ATA TGG ATG TGA CCA TCG CC - 3’ 
Reverse 3’ - GGC GAT GGT CAC ATC CAT ATT AAG GTA ACG GTA GG - 5’ 
 
3.1 Site-directed mutagenesis by PCR amplification 
 
The drUGM N372D and kpUGM D351N mutants were prepared by PCR based 
site-directed mutagenesis procedure using Stratagene (now Agilent) QuickChange tool 
kit. The plasmid DNA from the wild type was used as the template. The primers for site-
directed mutagenesis were designed using the program, MutaPrimeTM. Primers were 
obtained from AlphaDNA (AlphaDNA Inc). The components for PCR amplification and 
the protocol are shown in Table 3-1 and 3-2. Reactions were performed using a PTC-
100TM Programmable Thermal Controller (MJ Research Inc). After the reaction, the PCR 
product was digested with DpnI and transformed into E. coli NovaBlue cells. The cells 
were then plated and incubated at 37 oC overnight. Colonies were selected and inoculated 
into 10 ml of Luria-Bertani (LB) media and grown overnight at 37 oC. The cells were 
harvested and the cell pellet was used to perform plasmid DNA isolation using Qiagen 
plasmid isolation kit (QiaPrep). The concentration of isolated plasmid DNA was 
determined by a NanoDrop ND-1000 spectrophotometer (Thermo Scientific Inc) and the 
presence of the desired mutation was confirmed by DNA sequencing (Plant 
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Biotechnology Institute, Saskatoon). Sequencing results were analyzed with the program 
DNAMAN (Lynnon Biosoft Inc). 
Table 3-1 PCR reaction components for site-directed mutagenesis. 
S. No Reaction components Quantity 
1 Template DNA 50 ng 
2 Forward primer 125 ng 
3 Reverse primer 125 ng 
4 dNTP 1 µl 
5 Reaction buffer 5 µl 
6 Pfu Turbo DNA 
Polymerase 
1 µl 
7 RNAse free water 50 µl (Final volume) 
 
Table 3-2 Reaction conditions for PCR. 
Cycles Segment Temperature Time 
1 1 95 oC (Denaturation) 30 seconds 
2 95 oC (Denaturation) 30 seconds 
3 55 oC (annealing) 1 minute 
16 
4 72 oC (extension) 14 minutes (2 min/kb) 
1 5 25 oC (cooling) 2 minutes 
 
3.2 Determination of protein concentration  
Protein concentrations were determined by colorimetric method using the 
Bradford assay (Bradford, 1976). The cationic and anionic forms of the CoomassieR 
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Brilliant Blue G-250 dye has different absorption maximum (λmax) depending on the 
acidity of the solution. Under acidic conditions the anionic form (red) of the dye binds to 
the positively charged regions of the protein and the solution turns blue (cationic form of 
the dye). The absorbance of the resulting solution measured at 595 nm. Bovine serum 
albumin (BSA) was used as the standard. A series of dilutions were made from a BSA 
stock solution (10 mg/ml) to construct a standard curve. The concentration of unknown 
sample was determined from the regression equation obtained from the standard curve. 
All measurements were carried out using a Varian Cary 50 BIO UV-Visible 
spectrophotometer at 595 nm.   
3.3 Expression and purification of drUGM WT 
Previously, the gene encoding drUGM has been cloned (in our laboratory) into a 
pEHISTEV vector with an affinity tag at the N-terminus (six histidine residues). The 
construct (pEHISTEV vector with the drUGM gene) was transformed into E. coli Tuner 
cells (Novagen, USA). Transformed cells were grown in LB media with 50 µg/ml of 
kanamycin at 37 oC, until the optical density reached ~ 0.6 (at 600 nm), followed by 
induction with 0.4 mM isopropyl-β-thiogalactoside (IPTG) at 30 oC for 4-5 hours. Cells 
were harvested by centrifugation for 20 minutes (8000 rpm at 4 oC) and the resulting cell 
pellet was stored at -80 oC until purification. The frozen cell pellet was resuspended in 35 
ml of lysis buffer (100 mM potassium phosphate pH 8.0, 1 mM AEBSF (4-(2-
aminoethyl)-benzenesulfonyl fluoride), Triton-X 0.1 % v/v, DNase and lysozyme 20 
µg/ml) and stirred at 4 oC for 30 minutes, followed by sonication. The suspension was 
clarified by centrifugation at 18000 rpm for 30 minutes. The supernatant was subjected to 
heat denaturation at 55 oC for 10 minutes, followed by centrifugation at 18000 rpm for 30 
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minutes.  The supernatant was dialyzed against 25 mM potassium phosphate pH 8.0 (4 
changes). The dialyzed sample was filtered and applied to a HQ20 (Applied Biosystems, 
USA) anion-exchange column, pre-equilibrated with 25 mM potassium phosphate pH 8.0 
followed by gradient elution using 25 mM potassium phosphate buffer (pH 8.0) 
containing 1M NaCl. Fractions containing drUGM were collected, pooled and dialysed 
against 50 mM potassium phosphate pH 8.0. The sample was concentrated and brought to 
30 % w/v ammonium sulfate with stirring at 4 oC. The resulting solution was filtered and 
applied to a pre-equilibrated HP-20 (Applied Biosystems, USA) hydrophobic interaction 
chromatography column with the binding buffer (50 mM potassium phosphate pH 8.0 
containing 30 % ammonium sulfate). Bound proteins were eluted with decreasing 
gradient of ammonium sulfate in 50 mM potassium phosphate pH 8.0. Fractions 
containing drUGM were combined and dialyzed against 50 mM bis-tris propane pH 8.0. 
The purified drUGM was concentrated to 7.5 mg/ml (determined by Bradford assay) and 
the purity of the protein sample was judged from SDS-PAGE analysis (Figure 4-2). Small 
aliquots were flash-cooled using liquid nitrogen and stored at -80 oC. 
3.4 Expression and purification of drUGM N372D mutant 
drUGM N372D mutant was prepared by PCR-based site-directed mutagenesis 
method (See section 3.0 and 3.1). Expression and purification of the drUGM N372D 
mutant were similar as described for the drUGM WT (See section 3.3). Purified fractions 
were concentrated to ~ 7.5 mg/ml (as determined by Bradford assay).   
3.5 Expression and purification of mtUGM WT 
The gene encoding mtUGM was cloned into a pQE80 vector (in our laboratory) 
containing an affinity tag (six histidine residues) at the N-terminus.  The construct was 
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transformed into E. coli C43 (Qiagen) cells. Transformed cells were grown in Terrific-
broth medium with 100 µg/mL of ampicillin at 37 oC until the optical density reached ~ 
0.6 (at 600 nm) followed by induction with IPTG (0.5 mM) for 2 hours. The cells were 
harvested by centrifugation at 8000 rpm for 30 minutes. The resulting cell pellet was 
suspended in a lysis buffer containing 50 mM of sodium phosphate, 300 mM NaCl pH 
8.0, AEBSF (1mM final concentration), DNase (20 µg/ml) and lysozyme (20 µg/ml) and 
stirred at 4 oC for 30 minutes. Cells were further lysed by sonication and then centrifuged 
at 15000 rpm for 30 minutes. The supernatant was applied to a Protino Ni-IDA 1000 
prepacked columns  (Machery-Nagel) column (14 ml) preequilibrated with 50 mM of 
sodium phosphate, 300 mM NaCl, pH 8.0 (binding buffer). The column was washed with 
the binding buffer and the bound proteins were eluted using the elution buffer, 50 mM 
sodium phosphate, 300 mM NaCl and 250 mM imidazole pH 8.0. The individual 
fractions were analyzed for the presence of mtUGM by SDS-PAGE. Appropriate 
fractions were pooled and then dialyzed against 50 mM sodium phosphate buffer pH 7.0. 
The dialyzed sample was then concentrated and then frozen as small aliquots.  
3.6 Expression and purification of kpUGM D351N mutant 
kpUGM D351N mutant prepared by PCR-based site directed mutagenesis 
method. The primers and protocol for PCR are shown in section 3.0 and 3.1. kpUGM 
D351N mutant was expressed and purified in a manner similar to kpUGM WT (Chad et 
al, 2007). Briefly, the plasmid harboring kpUGM (in pEHISTEV vector) was transformed 
into E. coli Rosetta cells and gown in LB media at 37 oC (with kanamycin 50 µg/ml). 
When the optical density reached ~ 0.6 cells were induced with IPTG (0.4 mM final 
concentration) and incubated for a further 3-4 hours. The cell pellet was resuspended in a 
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lysis buffer (100 mM potassium phosphate pH 8.0, 2 mM AEBSF (4-(2-aminoethyl)-
benzenesulfonyl fluoride), DNase and lysozyme 20 µg/ml) and stirred at 4 oC for 30 
minutes. The cells further lysed by sonication. The suspension was clarified by 
centrifugation at 18000 rpm for 30 minutes. The supernatant was then treated with 10 % 
w/v of ammonium sulfate and stirred at 4 oC for 30 minutes. The solution was further 
clarified by spinning at 18000 rpm for 30 minutes. The supernatant was filtered and 
applied onto to a MC50 POROS column (Applied Biosystems) precharged with 50 mM 
CuCl2 and preequilibriated with the binding buffer (50 mM of phosphate buffer, 300 mM 
NaCl and 0.5 mM imidiazole). The bound proteins were eluted with a gradient of 0.5 to 
100 mM imidazole. Fractions were pooled, dialyzed and concentrated to 10 ml. The 
concentrated solution was brought to 40 % ammonium sulfate and then loaded onto a 
HP20 POROS hydrophobic column (Applied Biosystems) preequilibrated with the 
binding buffer (50 mM phosphate buffer, 40 % w/v ammonium sulfate, pH 8.0). The 
bound proteins were eluted with decreasing gradient of ammonium sulfate (from 40 to 0 
%) and appropriate fractions were pooled, dialyzed (with 50 mM Tris-HCl pH 7.5) and 
concentrated to 10 mg/ml. Small aliquots were flash-frozen with liquid nitrogen and 
stored at -80 oC.  
3.7 Kinetic characterization of drUGM WT and drUGM N372D mutant 
UGM assay was performed as described (Carlson et al, 2006) with necessary 
modifications. The reactions were carried out in 50 mM sodium phosphate buffer pH 7.0, 
containing 10 nM drUGM WT or drUGM N372D mutant, UDP-Galf (various 
concentrations) and freshly prepared sodium dithionite (20 mM final concentration). The 
volume of the reaction mixture was 100 µl. The time of each reaction was adjusted to 
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have 30-40 % conversion values (conversion of UDP-Galf to UDP-Galp). The reaction 
mixture was quenched by adding 100 µl of n-butanol.  The aqueous layer was collected 
and injected onto a CarboPac PA1 ion-exchange column (Dionex Inc) using a Waters 
HPLC system (Waters 510 pump connected to Waters 717 plus Autosampler and Waters 
2487 Dual λ Absorbance Detector). The sugar nucleotides were eluted isocratically with 
200 mM ammonium acetate pH 7.0 and the absorbance was set to 262 nm. Analysis of 
the HPLC chromatogram and integration of the peaks were carried out using Waters 
Millennium32 software (Version 4.0). The initial velocity was calculated from substrate 
concentration and % conversion. Kinetic values were determined from nonlinear 
regression analysis using GraphPad Prism software (GraphPad Software, San Diego 
California USA). 
3.8 Crystallization of drUGM-ligand complexes 
Initial crystallization trials to form drUGM:substrate complex were based on 
vapor diffusion methods by using various commercial broad screens (Hampton Research 
Inc). Crystal trials were carried out at 20 oC, room temperature (RT) and 4 oC. 
drUGM:UDP-Galp complex crystals were obtained by cocrystallization method. Hits 
were obtained from broad screens and further optimization around the hit condition was 
carried out (varying pH and precipitant concentration). Crystals obtained by vapor-
diffusion methods showed poor diffraction. Later changes were introduced in the 
cocrystallization setup and this involves chemical reduction of protein solution (by 
sodium dithionite) prior to substrate addition. After 20 seconds, substrate was added to 
the reduced protein solution with an incubation time of 5 minutes and then crystal trials 
were carried out. Crystals obtained in this manner showed improvement in diffraction. 
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Crystal conditions found in vapor diffusion methods were tried in the microbatch method 
(Chayen, 1997) and this showed improvement in diffraction. In addition, the effect of 
various cryoprotectants was studied and xylitol at 10-15 % was found to be optimal. 
Crystals frozen with xylitol as cryoprotectant showed better diffraction without forming 
ice-rings. Based on these results, the microbatch method was adopted for the 
crystallization of drUGM:substrate (and other ligand complexes) and are discussed below 
in detail.   
3.8.1 Crystallization of drUGM:UDP-Galp complex 
Crystals of drUGM:UDP-Galp (drUGMox) complex were grown using the 
microbatch method (Chayen, 1997). Prior to crystallization, protein solution (7.5 mg/mL) 
was reduced with sodium dithionite (20 mM final concentration) and mixed with UDP-
Galp (10 mM final concentration).  Equal volumes of protein solution and the 
crystallization solution, 0.1 M HEPES, pH 6.5, 0.2 M lithium chloride and 28 % PEG 
6000 were placed in the well and covered with paraffin oil. Crystals appeared within a 
week and were allowed to grow for two weeks. The crystals were bright yellow color and 
the maximum dimensions are 0.3 mm x 0.3 mm x 0.1 mm. Crystals were harvested 
placing them in the cryosolution (crystallization solution with 10 % xylitol and 15 mM 
UDP-Galp) and flash cooled with liquid nitrogen for data collection.  
3.8.2 Chemical reduction of drUGMox crystals 
Crystals of drUGMred (reduced drUGM:UDP-Galp complex) were obtained by 
chemical reduction of drUGMox crystals. A drop of cryosolution (0.1 M HEPES, pH 6.5, 
0.2 M lithium chloride, 28 % PEG 6000, 15 mM UDP-Galp and 10 % xylitol) containing 
20 mM of sodium dithionite was placed on a cover slip. Crystals of drUGMox were 
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looped and soaked in the cryosolution and observed under a microscope. Under these 
conditions, drUGMox crystals turned colorless (from yellow) and then immediately flash 
cooled with liquid nitrogen for data collection.  
3.8.3 Crystallization of drUGM:UDP complex 
Crystals of the drUGM:UDP complex were grown by the microbatch method 
using the crystallization conditions that gave drUGM-substrate crystals. Protein solution 
was reduced with sodium dithionite (20 mM final concentration) and mixed with UDP 
(10 mM final concentration). An equal volume of protein solution and crystallization 
solution was placed in the well and covered with paraffin oil. Crystals appeared within 5 
days and allowed to grow to their maximum dimensions for 2 weeks. drUGM:UDP 
crystals harvested by soaking the crystals in a cryosolution containing 15 mM UDP and  
flash cooled with liquid nitrogen.  
3.8.4 Crystallization of drUGM:UMP complex 
Crystals of the drUGM:UMP complex were grown by the microbatch method using the 
conditions that gave drUGM:UDP crystals. Protein solution was reduced with sodium 
dithionite (20 mM final concentration) and mixed with UMP (10 mM final 
concentration). An equal volume of protein solution and crystallization solution was 
placed in the well and covered with paraffin oil. Crystals appeared within 10-12 days and 
allowed to grow to their maximum dimensions for 3 weeks. Crystals of drUGM:UMP 
complexes were harvested by including 15 mM of UMP in the cryosolution and flash 
cooled with liquid nitrogen.  
3.8.5 Crystallization of drUGM:UDP-glucose complex  
Crystals of the drUGM-glucose complex were grown by the microbatch method  
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using the conditions similar to drUGM:UDP-Galp complexes. Protein solution was 
reduced with sodium dithionite (20 mM final concentration) and mixed with UDP-
glucose (10 mM final concentration). An equal volume of protein solution and 
crystallization solution was placed in the well and covered with paraffin oil. Crystals 
appeared within 7 days and allowed to grow to their maximum dimensions for 3 weeks. 
Crystals were harvested by including 15 mM of UDP-glucose (UDP-Glc) in the 
cryosolution and flash cooled with liquid nitrogen.  
3.8.6 Crystallization of drUGM:GCP complex 
GCP is substrate analog of UDP-Galp expected to act as an inhibitor of UGM 
(See section 5.0). Crystals of the drUGM:GCP complex were grown by the microbatch 
method using the conditions similar to drUGM:UDP-Galp complexes. Protein solution 
was first mixed with sodium dithionite and then GCP (10 mM final concentration) was 
added. The drUGM:GCP complex was incubated for 5 minutes and then crystallization 
trials were carried out. Equal volume of protein solution and crystallization solution was 
placed in a well and covered with paraffin oil. Crystals appeared within 2-3 weeks. 
Crystals were looped and placed in a cryosolution that contains 15 mM GCP and then 
flash cooled with liquid nitrogen. 
3.8.7 Crystallization of drUGM N372D:UDP-Galp complex 
Crystals of the drUGM N372D mutant were grown and harvested in a manner 
similar to drUGMox (See section 3.8.1).   
3.9 Data collection and processing 
X-ray diffraction data for all drUGM complexes were collected at the Canadian 
Light Source (CLS), Saskatoon, Canada (08ID-1 beamline at the CLS equipped with 
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Marmosaic225 CCD detector). The crystal-to-detector distance was set to 250 mm with 
an oscillation range of 0.25o and a total of 720 images (1 s exposure time for each image) 
were collected that covered a total oscillation range of 180o. All datasets except drUGMox 
were processed using the program D*TREK (Pflugrath, 1999). drUGMox was processed 
using XDS (Kabsch, 2010b). Data collection and refinement statistics summarized in 
Table 4-3, 4-5, 4-6, 5-2 and 5-8. 
3.10 Structure determination and refinement 
The structure of the drUGM:substrate (drUGMox) complex was determined by the 
MR method by using the MOLREP (Vagin & Teplyakov, 2010) option from MrBUMP 
(Keegan & Winn, 2008)  within the CCP4 package (Winn, 2003). The structure solution 
was found by using UGM from M. tuberculosis (mtUGM) as the search model (Beis et 
al, 2005). The initial solution had 8 copies of the monomer in the asymmetric unit (asu). 
This solution was fixed and a search for additional copies gave a model with 10 copies of 
the monomer in the asu. Refinement was carried out using REFMAC5 (Murshudov et al, 
1999) and PHENIX (Adams et al, 2010; Adams et al, 2002). The structure of drUGMred 
and drUGM:UDP complexes were determined by molecular replacement using the 
monomer of drUGMox. The restraints for UDP-Galp and reduced FAD were generated by 
using ELBOW implemented within PHENIX (Adams et al, 2010; Adams et al, 2002). 
Other drUGM:ligand complexes were determined by using drUGMox (after removing 
ligands) as the starting model for refinement. Model building was performed using Coot 
(Emsley & Cowtan, 2004). The final structures were evaluated using the PDB validation 
server. Accessible area was calculated using AREAMOL program within the CCP4 
package. All molecular graphics were generated using PYMOL (Delano Scientific, 2002) 
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3.11 Evaluation of inhibitors 
Enzyme inhibition assays were performed as described with necessary 
modifications (Carlson et al, 2006). Reactions were monitored in the reverse direction, 
conversion of UDP-Galf to UDP-Galp, in the presence and absence of inhibitor. The 
extent of inhibition was expressed as % inhibition at a given concentration of the 
inhibitor. A time-point was chosen that gave ~ 50 % conversion of UDP-Galf to UDP-
Galp for the evaluation of inhibitors (drUGM WT 2 minutes; drUGM N372D 3 minutes; 
kpUGM WT 2 minutes; mtUGM 1.30 minutes; kpUGM D351N 5 minutes). All reactions 
were carried out in a freshly prepared 50 mM sodium phosphate buffer, pH 7.0. Reaction 
vials and other solutions were degassed with argon. The enzyme (kpUGM 10 nM , 
drUGM WT 10 nM, drUGM N372D 50 nM, kpUGM D351N 600 nM and mtUM 87 nM) 
was first reduced with sodium dithionite (20 mM final concentration) and then incubated 
with inhibitor at 1 mM concentration for 5 minutes (for kpUGM D351N 7 minutes) and 
then UDP-Galf was added to the reaction mixture (20 µM final concentration) and the 
reaction was allowed to proceed at room temperature. The reaction mixture was 
quenched with 100 µl of n-butanol. The aqueous layer was collected and injected into a 
CarboPac PA1 column (Dionex Inc), preequilibrated with 200 mM ammomuin actetate, 
pH 7.0. The sugar nucleotides were eluted isocratically using 200 mM ammomuin 
actetate, pH 7.0 with a flow-rate of 1.0 ml/minute. The two sugar-nucleotides separated 
with base-line resolution, and the extent of conversion was determined by integration of 
the two peaks (Equation 3-1). 
% conversion  =            area of UDP-Galp peak                                      X 100   (3-1)                   
                   [(area of UDP-Galp peak) + (area of UDP-Galf peak)]   
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The percentage inhibition was calculated from the turn-over of inhibited reactions 
compared to the reactions with no inhibitor. 
3.12 Synthesis of UDP-Galf 
UDP-Galf was synthesized by a chemo-enzymatic method as described (Rose et 
al, 2008). The steps involved in the preparation of UDP-Galf are discussed below. 
3.12.1 Expression of GalPUT 
GalPUT (Galactose-1-phosphate uridyl transferase) is an enzyme that catalyzes 
the transfer of UMP unit from UDP-Glc to galactofuranose-1-phosphate to form UDP-
Galf. GALU (Glucose-1-phosphate uridyl transferase) catalyzes the transfer of UMP 
from UTP to glucose-1-phosphate to form UDP-Glc. 
The plasmid harboring the GalPUT gene was a generous gift from Dr. Rob Field 
(University of East Anglia, UK). The construct was transformed into E. coli BL21 cells. 
The cells were grown in LB media at 37 oC (100 µg/ml ampicillin) then induced with 
1mM IPTG when the optical density reaches 0.6-0.8 units. Cells were allowed to grow at 
30 oC for another 5 hours. The cells were then harvested by centrifugation at 8000 rpm 
and the cell pellet was stored at -80 oC until purification.   
3.12.2 Purification and Immobilization of GalPUT 
The cell pellet was thawed on ice and resuspended in 35 mL of resuspension 
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0. To this, AEBSF (1 
mM final concentration), lysozyme 50 µl (from 20 mg/ml stock) and DNase 50 µl (from 
20 mg/ml stock) were added and stirred at 4 oC for 30 minutes. Cells were further lysed 
by sonication. The suspension was centrifuged at 18000 rpm for 30 minutes. The 
supernatant was filtered and applied onto a preequilibrated (50 mM NaH2PO4, 300 mM 
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NaCl, 10 mM imidazole, pH 8.0) Ni-NTA agarose column with a flow rate of 0.7-1.0 
ml/min. The low flow rate is to ensure that there is enough time for GalPUT to interact 
with Ni-NTA. Unbound proteins were removed by wash buffer (50 mM NaH2PO4, 300 
mM NaCl, 10 mM imidazole, pH 8.0) until the absorption at 280 nM returned to baseline. 
Then 2 column volumes of GalPUT reaction buffer (50 mM HEPES, 10 mM MgCl2, 
5mM KCl, pH 8.0) was used to rinse the column and the immobilized GalPUT was 
stored in this buffer for the next step.   
3.12.3 Coupling of UMP to Galf-1-phosphate 
UTP (23 mg, 40 µmol) and Galf-1-phosphate (14.8 mg, 40.5 µmol) were 
dissolved in 0.6 ml of GalPUT reaction buffer. GALU (Glucose-1-phosphate 
uridyltransferase, 5U), inorganic pyrophosphatase (5U) and the immobilized resin 0.7–
1.0 ml were added to the above solution. The reaction was initiated by the addition of 
UDP-Glc (0.15 µmol). The resulting mixture was flushed with nitrogen and the reaction 
stirred at room temperature. The progress of the reaction was monitored by HPLC using 
analytical reverse phase C18 column (4.6 x 250 mm) using 50 mM 
triethylammoniumacetate containing 1.5 % acetonitrile with a flow rate of 1.0 ml/min. 
The reaction was allowed to proceed until optimal conversion had taken place (~ 24 
hours).  
3.12.4 Separation of UDP-Galf  
The removal of immobilized GalPUT and other enzymes from the reaction 
mixture was accomplished by centrifugation using WMCO 10 kDa Amicon centrifugal 
filter devices. The final volume of the solution was made to 5 mL for the first desalting 
step. A sephadex G-15 (3 x 95 cm) column was used to remove salts from the reaction 
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buffer. Fractions containing UDP-Galf were pooled together and concentrated at 25 oC ( 
~ 10 mL).  Unreacted UTP and other impurities were removed by a preparative HPLC 
procedure (preparative C18 reverse phase column) using 5 mM sodium phosphate buffer, 
pH 6.8 with a flow rate of 5 ml/min. The retention time for UDP-Galf was between 11-12 
minutes. Appropriate fractions were pooled and concentrated at 25 oC (~ 10 ml) and used 
for next desalting step. Removal of salt was achieved by using Sephadex G-15 column (3 
x 95 cm). Fractions were collected and concentrated to less than 10 mL and then 
subjected to lyophilization.  
3.13 Docking studies of inhibitors 
Docking studies were performed using the program Surflex-DockTM from Tripos 
Inc. (Jain, 2003). Structures of inhibitor molecules were sketched and minimized using 
SYBYL 8.0 (Tripos, Inc). Coordinates of the drUGM:substrate complex (reduced) for 
docking studies (Partha et al, 2009). Hydrogen atoms were added to the protein molecule 
and then energy minimized. The active site was defined using UDP-Galp as the reference 
molecule. All default parameters were used for docking studies and 10 docked 
conformations were requested.  
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CHAPTER 4 
drUGM-ligand structures 
4.0 UGM from Deinococcus radiodurans (drUGM) 
Previous attempts to crystallize a UGM:substrate complex (either by soaking or 
cocrystallization) were unsuccessful in forming substrate bound crystals (Beis et al, 2005; 
Sanders et al, 2001). It has been proposed that the mobile loop located at the entrance of 
the substrate binding cleft may affect the formation of substrate bound crystals, either by 
soaking or cocrystallization (Chad et al, 2007). Due to the existing difficulties (with 
ecUGM, kpUGM and mtUGM) in forming UGM:substrate complex crystals, the  source 
of the enzyme was changed. I used the UGM homolog from an alternate organism. This 
approach (using alternate homologs) has been proven to be successful in the 
crystallographic investigation of many proteins (Campbell et al, 1972; Derewenda, 2004; 
McPherson, 2004). UGM from D. radiodurans (drUGM) was used as an alternative 
source to determine the UGM:substrate complex structures. drUGM has sequence 
identities of 37 %, 42 % and 39 % to ecUGM, kpUGM and mtUGM respectively (Figure 
4-1). The amino acid residues involved in FAD binding and in the active site are 
conserved in drUGM (Table 4-1). Based on these facts, the drUGM:substrate complex 
could be considered as a template for understanding the UGM:substrate structure and the 
active site interactions.   
4.1 Purification and kinetic characterization of drUGM (WT) 
The presence of an affinity tag in drUGM (six histidine residues) at the N-
terminus did not help to purify the enzyme by affinity chromatography. Hence, drUGM 
was purified in two steps, anion-exchange chromatography followed by hydrophobic 
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Figure 4-1 Sequence alignment of drUGM with other bacterial UGMs. The secondary 
structures shown above and below the sequences are based on the crystal structure of 
drUGM-substrate complex and kpUGM (PDB Code: 2BI7). The active site residues are 
shown as red asterisks, conserved residues of the FAD binding domain are highlighted in 
blue triangles, the mobile loop indicated by yellow bars. The conserved Arg364, which 
shows different orientation in the complex structure, is highlighted in green asterisk. 
Figure generated using ESpript (Gouet et al, 1999; Gouet et al, 2003).  
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Table 4-1 Sequence numbers for conserved active site residues of UGM from K. 
pneumoniae, E. coli, M. tuberculosis and D. radiodurans. 
 
 
K. pneumoniae  E. coli   M. tuberculosis                        D. radiodurans 
 
H60   H56   H65   H88 
Y155   Y151  Y161   Y179 
W160   W156  W166   W184 
R174   R170   R180   R198 
Y185   Y181   Y191   Y209 
R280   R278   R292   R305 
E301   E298   E315   E325 
Y314   Y311   Y328   Y335 
Y349   Y346   Y366   Y370 
N84  N80  H89   H109 
T156  T152  T162   T180 
R343                    R 340                    R360  R364 
N270                    N268                    N282                                  N296 
F151                     L147                    F157  F175 
F152  I148 V158                                   F176 
D351   D348   D368   N372 
 
 
chromatography. The purity of the sample was judged by SDS-PAGE analysis (Figure 4-
2). Steady-state kinetic analysis of drUGM (WT) was carried out to compare its kinetic 
parameters with other bacterial UGMs. The forward reaction, conversion of UDP-Galp to 
UDP-Galf is difficult to monitor by HPLC as the equilibrium is 93 (pyranose form):7 
(furanose form) for the forward reaction. The standard UGM assay is based on 
monitoring the reverse reaction, i.e., conversion of UDP-Galf to UDP-Galp and 
separating the two sugar nucleotides on a HPLC column (Carlson et al, 2006; Zhang & 
Liu 2001). The separation of sugar nucleotides were done using a CarboPac PA1 column 
(Carlson et al, 2006), although, C18 reverse phase columns were used by others 
(Caravano et al, 2003; Zhang & Liu 2001). The separation of sugar nucleotides was better 
with the CarboPac PA1 column as compared to C18 reverse phase columns. All reactions 
were carried out at room temperature in the presence of sodium dithionite (20 mM).  The 
standard Michaelis-Menten saturation curve for each concentration of substrate is shown 
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in Figure 4-3.  The kinetic parameters of drUGM WT were comparable to other bacterial 
UGMs (Table 4-2).  
 
        
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2 SDS-PAGE analysis of purified fractions of drUGM. Lane 1 low molecular 
weight marker, lane 2 supernatant after cell lysis, lane 3 fractions after anion-exchange 
chromatography, lane 5 (10 µl) and lane 6 (15 µl) fractions after hydrophobic 
chromatography. 
 
 
 
 
 
 
 
 
 
 
Figure 4-3 Saturation curve for drUGM for each concentration of the substrate. 
4321 5
45 kDa
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Table 4-2 Kinetic data for drUGM and other bacterial UGMs. 
Enzyme kcat(s-1) Km (µM) kcat/ Km (µM-1 s-1) 
ecUGM1 22  27 0.81 
kpUGM2,3 5.0 ± 0.6  45 ± 6.0 0.11 
drUGM4 66 ± 2.4 55 ± 7.0 1.18 
 
1The authors of this paper (Zhang & Liu, 2000) did not report the errors for the kinetic 
parameters. 
2(Chad et al, 2007). 
3A Km value of 16 µM and kcat of 2210 min-1 reported for kpUGM with 5-10 % error in 
the data (Errey et al, 2009). 
4Kinetic values reported in this thesis. 
 
4.2 Structure of oxidized drUGM:UDP-Galp complex (drUGMox) 
Crystals of drUGMox were grown by cocrystallization using the microbatch 
method (Karunan Partha et al, 2009). The drUGMox complex crystallized in the P212121 
space group and the crystals diffracted to 2.4 Å. Data collection and refinement statistics 
are shown in Table 4-3. The structure solution was obtained by molecular replacement 
(MR) by using mtUGM (PDB code: 1V0J) as the search model (Beis et al, 2005). The 
MOLREP program (Vagin & Teplyakov, 2000) implemented within MrBUMP (Keegan 
& Winn, 2008) was used for the MR search.  The crystals of drUGMox contain 5 
homodimers in the asymmetric unit (asu), all identical. The electron density for the sugar 
(galactose) moiety in drUGMox was weak; therefore, NCS averaging over the 10 active 
sites was carried out to generate an averaged map for modeling the galactose portion of 
the substrate in the drUGMox. 
UGM is a homodimer and belongs to the α/β class of protein. Each monomer of 
UGM can be divided into three distinct domains (Figure 4-4). Domain 1 is the binding 
site for FAD, containing the αβα Rossmann fold.  Domain 2 is a five-helix bundle and 
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domain 3 is a six-stranded anti-parallel β-sheet. The substrate binding site is located in a 
cleft adjacent to the isoalloxazine ring of FAD. Two flexible loops (loop 1 and loop 2)  
 
Table 4-3 Data collection and refinement statistics. 
 
 
  
drUGMox 
 
drUGMred 
 
drUGM:UDP 
 
Data collection 
   
Space group P212121 P212121 P212121 
Cell dimensions      
    a, b, c (Å) 134.0, 176.6, 221.6 132.8, 174.6, 218.1 134.05, 176.87, 222.9 
 90.00, 90.00, 90.00 90.00. 90.00, 90.00 90.00, 90.00, 90.00 
Resolution (Å) 2.36 (2.42-2.36) 2.50 (2.59-2.50) 2.55 (2.649-2.55) 
Rsym  11.6 (68.9) 18.0 (61.0) 17.2 (57.8) 
I / σI 13.0 (3.0) 5.5 (1.9) 7.2 (1.0) 
Completeness (%) 95.8 (87.4) 96.3 (93.9) 98.9 (93.1) 
Redundancy 7.2  4.8 7.9 
 
   
Refinement    
Resolution (Å) 20.0-2.36 40.0-2.50 40.0-2.55 
No. reflections 204925  168600 204114 
Rwork / Rfree 0.17/0.22 0.21/0.27 0.18/0.24 
No. atoms    
    Protein 30998 30009 30748  
    Ligand (FAD and UDP-
Galp) 
880 880 780 
    Water (molecules) 1241 556 1096 
B-factors    
    Protein 36.0 53.8 44.6 
    Ligand 39.3 (UDP-Galp) 
37.9  (FAD)                          
 
51.9 (UDP-Galp) 
53.2 (FAD) 
41.7 (UDP) 
44.5 (FAD) 
    Water 41.5 47.8 43.4 
r.m.s. deviations    
    Bond lengths (Å) 0.008 0.009 0.009 
    Bond angles (°) 
 
1.2 1.2 1.2 
*values in the parenthesis are for the highest resolution shell 
 
are located at the entrance of this cleft and are believed to move upon substrate binding 
(Sanders et al, 2001). 
The overall structure of drUGMox is similar to the other bacterial UGM structures, 
except for the mobile loop conformation (loop 1 and 2) (Figure 4-4). To date, efforts    
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C              D 
 
 
 
 
Figure 4-4 Crystal structure of drUGM-substrate complex. (A) Ribbon diagram 
representation of a monomer of drUGMox. Domain 1 (FAD binding domain), 2 and 3 are 
colored blue, green and gray respectively while the flexible loop 1 and 2 are colored red. 
The substrate (UDP-Galp) and FAD are rendered as sticks. (B) Superposition of kpUGM 
(cyan) with drUGMox (green). Note the closed conformation of the loop 2 in drUGMox. 
(C) Comparison of the flavin conformation in drUGMox (green) and drUGMred (blue). 
(D) Overlay of drUGMox (green) and drUGMred (blue). The N5 of FAD in drUGMred is 
close to the C1 of the galactose.   
 
to determine the structure of unliganded of drUGM were unsuccessful. But, it is expected 
that the structure of unliganded drUGM will be similar to the other unliganded bacterial 
UGMs. In order to compare the drUGM:substrate complex structure with the substrate 
 
N5 (FAD) 
 
(UDP-Galp) C1 
N5 (FAD) 
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free UGM structure, unliganded kpUGM was used (Beis et al, 2005). The sequence 
identity between kpUGM and drUGM is 42 %. Monomer A from drUGMox could be 
superimposed with monomer A of kpUGM with a rmsd value of 1.4 Å for 350 equivalent 
Cα atoms including the two mobile loops (Figure 4-4). The individual domains have rmsd 
values of 0.9 Å, 1.9 Å and 1.4 Å for domain 1, 2 and 3 respectively. Domain 2 and 3 
contains most of the active site residues, while domain 1 is primarily involved in FAD 
binding.  
4.3 Structure of reduced drUGM:UDP-Galp complex (drUGMred) 
Crystals of drUGMox were reduced chemically with sodium dithionite to obtain 
drUGMred crystals. After brief exposure to sodium dithionite, the crystals turned from 
yellow to colorless, indicating that flavin was reduced. The structure of drUGMred was 
solved by molecular replacement with MOLREP (Vagin & Teplyakov, 2000) using 
monomer A of drUGMox. drUGMred crystals diffracted to 2.5 Å. Data collection and 
refinement statistics are shown in Table 4-3. The overall structure of drUGMox and 
drUGMred are similar (including the two flexible loops), with a rmsd value of 0.72 Å over 
all equivalent Cα atoms (Partha et al, 2009). Notable differences between drUGMox and 
drUGMred are the electron density for the sugar moiety and the FAD conformation 
(Figure 4-4). The electron density for the sugar moiety is well defined in drUGMred 
compared with drUGMox, suggesting stabilization of the sugar conformation in reduced 
UGM (Figure 4-5). The isoalloxazine ring of FAD in the drUGMred structure showed a 
bent conformation with the N5 of FADH- pointing towards the sugar moiety of the 
substrate. In drUGMred the density of FAD in some monomomers corresponded to 
oxidized FAD.  It is possible that there is a mixed population of oxidized and reduced 
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C       D    
    
 
 
 
 
 
 
 
Figure 4-5 Electron density maps of UDP-Galp A) Omit map of drUGMred contoured to 
2.0 σ calculated after simulated annealing without FAD and UDP-Galp. FAD and UDP-
Galp are modeled into the density for further refinement. B) The refined 2Fo-Fc map of 
drUGMred contoured to 1.0 σ. Note the residual density between the N5 of FAD and the 
sugar moiety of the substrate. C) NCS averaged difference omit map (contoured at 4.0 σ) 
of the substrate in drUGMox. D) Difference map of the substrate in drUGMred (chain D) 
contoured to 2.0 σ. The density for the sugar moiety is well defined in D (drUGMred) 
compared to C (drUGMox).  
 
N5 (FAD) 
(UDP-Galp) C1 
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FAD in the crystals.The density for reduced FAD was observed in chain B, D and G. The 
distance between N5 of FAD to the anomeric carbon of galactose in drUGMox and 
drUGMred was found to be 3.3 Å and 2.8 Å respectively (Figure 4-4). The residual 
density between the reduced FAD and the sugar moiety was observed only in chain D 
and is suggestive of bond formation between them (Figure 4-5). Previously, a tryptophan 
fluorescence assay showed that reduced UGM has a 3-fold greater affinity for substrate 
than oxidized UGM (66 µM vs. 220 µM) (Yao et al, 2009).  The structural observations 
for drUGMred, including the stabilized sugar conformation and possible bond formation 
are consistent with these previous studies.  
4.4 Substrate binding model 
The binding mode of the substrate and its active site interactions are shown in 
Figures 4-6, 4-7, 4-8 and 4-9. The substrate is buried in the active site with only 6.0 Å2 
(0.85% of the total surface area) exposed to the bulk solvent (Figure 4-6A) and is bound 
in a folded U-shaped conformation (Partha et al, 2009).  
The binding mode of UDP-Galp in drUGM is remarkably different from the fully 
extended or folded conformations of UDP-Galp (or fluoro analog of UDP-Galp) observed 
in the structures of other enzymes (Figure 4-6B), such as α-1,4-galactosyltransferases 
(from Neisseria menintigitidis) and UDP-galactose-4-epimerase (Persson et al, 2001; 
Thoden & Holden, 1998). Based on the substrate (UDP-Galp) structure, the active site of 
UGM can be divided into three different regions, namely, the uridine binding pocket, the 
phosphate binding region and the sugar binding cleft.  
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Figure 4-6 Binding mode of UDP-Galp. A) Surface representation of drUGMox. 
Substrate and FAD represented as sticks. The surface (red, negatively charged region; 
blue, positively charged region) is rendered transparent to highlight the buried substrate. 
B) Comparison of UDP-Galp binding conformation in different crystal structures. 
Conformation in drUGMox 1, UDP-galactose epimerase 2 (PDB code 1A9Z) and in 
galactosyltransferase 3 (PDB code 1G9R).  
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4.4.1 Uridine binding pocket  
In drUGM:substrate complex structures, residues in the uridine binding pocket 
(Figure 4-7) showed very little movement when compared with the unliganded UGM 
(Partha et al, 2009; Sanders et al, 2001). Interactions in this region are dominated by a 
network of hydrogen bonds between the uridine moiety and the side chain of amino acid 
residues. Based on modeling and kinetic studies, an active site tryptophan (Trp160 in 
kpUGM) was identified and assigned a critical role in substrate binding and activity 
(Chad et al, 2007). Modeling suggest that Trp160 can form pi-stacking intractions with 
uracil ring of the substrate (Chad et al, 2007; Sanders et al, 2001; Yuan et al, 2008). In 
A             B 
 
 
 
 
 
 
 
 
Figure 4-7 Active site interactions of UDP-Galp at the uridine binding pocket. A) 
Overlay of unliganded kpUGM and drUGMox to highlight the orientation of residues in 
uridine binding region. B) Active site interactions at the uridine binding pocket. Water 
molecules represented as red spheres. 
 
drUGM:substrate complex structures the uracil ring is stacked between Tyr179 and 
Phe176 (3.9 Å from the centre of the aromatic ring of Tyr 179 to the centre of uracil ring 
and 4.8 Å for the corresponding distance between Phe 176 and the uracil). The indole NH 
N296
F176
Y179
T180
F175
W184
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of Trp184 (Trp160 in kpUGM) form hydrogen bonds with the C3’ (2.8 Å) and C2’ (3.3 
Å) hydroxyl groups of ribose. This is still consistent with a critical role for Trp184 in 
substrate binding. A similar binding mode for the uridine moiety has been suggested in 
other modeling studies (Bleile, 2008) and is also seen in the kpUGM:UDP-Galp complex 
structure (See section 4.6) (Gruber et al, 2009a; Gruber et al, 2009b). Additional 
hydrogen bonds are formed between O2, O4 and N3 of uracil with Thr180, Asn296 and 
Phe175 respectively. The C2’ hydroxyl group of ribose also forms a hydrogen bond with 
the Oγ1 of the conserved Thr180. The only observed conformational change in the 
uridine binding pocket is the orientation of Gln183 side chain (from domain 2). In 
drUGMox and drUGMred the side chain of Gln183 is oriented away from the active site. In 
unliganded UGM structures the corresponding Gln is directed towards the active site. 
This conformational change is likely to avoid steric clashes between the substrate (ribose 
moiety) and the side chain of Gln183.  
4.4.2 Phosphate binding region 
The two phosphate groups (α and β) of the substrate form salt-bridges with the 
highly conserved arginines, Arg198 and Arg305 (Figure 4-8). Notably, Arg198 located in 
the mobile loop 2 stabilizes the α-phosphate of the substrate and the β-phosphate group is 
stabilized by Arg305. Mutation of either residue (mutants of kpUGM, R174A and 
R280A) abolish enzyme activity (Chad et al, 2007). The two phosphate groups of the 
substrate are further stabilized by hydrogen bond formation with conserved tyrosines 
(Tyr209, Tyr370 and Tyr335). These residues were shown to be important for substrate 
binding (Chad et al, 2007; Sanders et al, 2001). Three water molecules located in the 
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active site function as bridges to form hydrogen bonds between the two phosphate groups 
and the side chains of active site residues.   
 
 
 
 
 
 
 
 
 
 
Figure 4-8 Active site interactions of UDP-Galp at the phosphate binding region. 
 
4.4.3 Sugar binding cleft 
The sugar (galactose) moiety of the substrate occupies a pocket adjacent to the 
isoalloxazine ring of FAD (Figure 4-9). It is stabilized primarily through water mediated 
hydrogen bonds with the side chains of His88, His109, Arg364, and Asn372.  Tyr371 
forms water mediated hydrogen bonds with the sugar moiety through its backbone 
carbonyl oxygen atom. The C2 and C3 hydroxyl groups of galactose are involved in 
water mediated hydrogen bonding with His88, Asn372, Arg364 and Tyr371. C4 and C6 
hydroxyl groups form direct hydrogen bonds with O4 of FAD and NE1 of His109 
respectively. The hydrogen bond between O4 of FAD and the C4 hydroxyl group of 
galactose plays an important role in substrate recognition and activation of the C4 
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hydroxyl group. The C4 hydroxyl of galactose (axial orientation) can form strong 
hydrogen bond interactions with O4 of FAD. This interaction may be weak if the C4 
hydroxyl group is equatorial (in UDP-Glc). This may account for the specificity of UGM 
for UDP-Galp over UDP-Glc (See section 4.10). This hydrogen bond between the O4 of 
FAD and the C4 hydroxyl group may assist in the removal of a proton from the C4 
 
 
 
 
 
 
 
 
 
 
Figure 4-9 Active site interactions of UDP-Galp at the sugar binding cleft. 
 
hydroxyl group and increase its nucleophilicity to initiate the ring closure step (Figures 1-
4 and 1-5). The anomeric carbon of galactose in drUGMred is located at a distance of 2.8 
Å from N5 of FADH-. The proximity of the anomeric carbon to N5 of FADH- is 
favorable to form a FAD-galactosyl adduct and is consistent with the proposed role for 
FAD in the reaction (Huang et al, 2003; Soltero-Higgin et al, 2004). Overall, the UDP 
portion of the substrate is stabilized by interactions with active site amino acid residues, 
while the sugar moiety interacts mainly through water mediated hydrogen bonds. This 
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pattern of interaction is consistent with the STD-NMR studies of UGM-substrate 
interactions, where the protons of the UDP moiety showed the largest STD effects (Yuan 
et al, 2005).  The binding mode of substrate is also consistent with the recent report on 2- 
3- and 6-fluoro-substituted UDP-Galp analogs that were found to be substrates for 
kpUGM (Errey et al, 2009).  It has been shown that none of the 2, 3 and 6-hydroxyl 
groups of galactose in UDP-Galp are essential for substrate binding and turnover. In 
drUGM:UDP-Galp complex structures, the C2 and C3 hydroxyl groups of galactose are 
not involved in direct contact with any amino acid residues and they form water mediated 
hydrogen bonds. The C6 hydroxyl group forms a hydrogen bond with His109 (3.3 Å). 
These fluoro analogs are capable of forming hydrogen bonds and were able to act as 
substrates for UGM. Analogs with the C2 hydroxyl in axial orientation, namely, UDP-
talose and UDP-2-deoxy-2-fluoro-talose (2-fluoro in axial orientation) are not substrates 
of UGM (Errey et al, 2009). The drUGM:substrate complex structures provide a 
molecular basis for the inability of UDP-talose or UDP-2-deoxy-2-fluoro-talose to act as 
substrate or inhibitor for UGM. The substrate binding mode in drUGM suggests that C2 
axial substitutions would result in severe steric clashes with FAD and thus any efforts to 
prepare C2 axial substituent may render the compound inactive.  
4.5 Rearrangement of flexible loop 
Based on the structural, modeling and biochemical studies on UGM it has been 
proposed that the two mobile loops undergo rearrangement upon substrate binding (Chad 
et al, 2007; Sanders et al, 2001). Most importantly, mobile loop 2 undergoes significant 
rearrangement upon substrate binding from an open to closed conformation. In 
drUGM:substrate complex structures the mobile loops (loop 1: 149-157 and loop 2: 185-
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215) have moved significantly towards the substrate binding pocket and exist in a closed 
conformation as compared to the open conformation in other bacterial unliganded UGMs 
(Figure 4-10). The distance between the Cα of Arg198 (in drUGM:substrate complex) and 
the corresponding arginine in unliganded UGMs is ≥ 7.0 Å (Table 4-4). Arg198 of the 
mobile loop 2 stabilizes the closed conformation by forming salt-bridges with the α-
phosphate group of the substrate and also by cation-pi interaction with Tyr370. In 
ecUGM, monomer A and B exist in a closed and open conformation respectively 
(Sanders et al, 2001). Overlay of monomer A of ecUGM (closed conformation) with the 
substrate complex structure is shown in Figure 4-10. The conserved arginine (Arg170 in 
ecUGM) of the flexible loop is pointing away from the active site, whereas in 
drUGM:substrate complex structures the corresponding arginine (Arg198) orients 
towards the substrate and stabilizes its α-phosphate group (2.8 Å from Nε of Arg198 to 
the oxygen of the α-phosphate group). drUGM:substrate complex structures reveal the 
structural and functional role of the conserved arginine (Arg198) of the flexible loop and 
it is consistent with the other biochemical studies (Chad et al, 2007; Yao et al, 2009; 
Yuan et al, 2008). 
Table 4-4 Distance between the Cα of Arg198 (drUGM:substrate complex) and the 
corresponding arginine in other bacterial UGMs. 
 
 
 
 
 
 
 
 
*Athough monomer A of ecUGM is in a closed conformation, the side chain of Arg170 is 
pointing away from the substrate binding cleft (Figure 4-8B). 
 
 
Enzyme Residue 
Number 
Distance (Å) 
ecUGM (monomer B) R170 7.0 
ecUGM (monomer A) R 170 2.2* 
kpGM R174 10.3 
mtUGM R180 8.5 
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Figure 4-10 Conformational changes in drUGM:substrate complex structures (A) 
Comparison of flexible loop conformation of drUGM:substrate complex with unliganed 
UGMs. drUGMox (green), kpUGM (red), ecUGM, monomer B (blue) and mtUGM 
(yellow). (B) Overlay of structures of drUGMox (green) and closed conformer of 
monomer A of ecUGM (Cyan). Arg170 (in ecUGM) of the flexible loop is facing away 
from the substrate binding site while the corresponding arginine of  drUGMox (Arg198) 
point towards the substrate binding pocket and stabilize the α-phosphate group of UDP-
Galp. 
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4.6 Conformational changes in FAD binding domain 
In drUGMox and drUGMred, the side chains of Arg364 and Tyr370 showed 
significant differences in their orientation when compared with the unliganded UGMs 
(Figure 4-11). In the unliganded UGM structures the corresponding side chains of 
arginine and tyrosine interact with the phosphate group and N10 of FAD respectively 
(Arg343 and Tyr349 in kpUGM). In the drUGM:substrate structures the side chain of 
Arg364 is oriented towards the active site and forms a water-mediated hydrogen bond 
with the C2 hydroxyl group of galactose (Partha et al, 2009). The side chain of Tyr370 
(in drUGM:substrate complex) is tilted at an angle of ~ 45º (as compared to Tyr349 of 
kpUGM) and interacts with the α-phosphate group of the substrate. The side chain of 
Tyr370 forms hydrogen bonds with the phosphate group of the substrate and the aromatic  
 
 
 
 
 
 
 
Figure 4-11 Overlay of structures of drUGMox and unliganded kpUGM. Note the 
orientation of the Arg364 and Tyr370 of drUGMox and the equivalent residues in kpUGM 
(Arg343 and Tyr349). 
 
ring is stacked against Arg198 (cation-pi interactions). It is possible that these 
conformational changes lock the entrance of the pocket (together with the Arg198) and 
act as a gateway for the entrance and release of the substrate and product.  
Y370
Y349
R343
R364
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4.7 Comparsion of drUGM:UDP-Galp and kpUGM:UDP-Galp complexes 
Structures of drUGM:substrate complexes were the first substrate bound structure 
for any UGM to be deposited in the PDB (3HDQ and 3HDY). Later, structures of 
oxidized and reduced kpUGM:substrate complexes were reported after we submitted our 
results for publication (Gruber et al, 2009b; Partha et al, 2009). drUGM and kpUGM 
share 42 % sequence identity and the active site residues are conserved between them. 
The overall structure, binding mode and active site interactions between the two 
complexes are expected to be similar. Indeed, the overall structures of the two complexes 
were similar, but major differences between oxidized substrate complexes (drUGMox vs 
kpUGMox) and minor differences between reduced substrate complexes were observed 
(drUGMred vs kpUGMred). In kpUGMox, the mobile loops in monomer A and B don’t 
exist in an open conformation, while in drUGMox a fully closed conformation observed in 
all the chains. (Figure 4-12). The binding mode of UDP-Galp in kpUGMox is 
significantly different in kpUGMox when compared with drUGMox. For example, the 
stabilization of the phosphate groups by the two conserved arginines (Arg174 and 
Arg280) is completely missing in kpUGMox, whereas in drUGMox the two conserved 
arginines (Arg198 and Arg305) are in close contact with the phosphate groups of the 
substrate. The location of the sugar moiety and its binding mode is also significantly 
different in kpUGMox when compared with drUGMox. The sugar moiety is located at the 
entrance of the binding cleft in kpUGMox. In drUGMox the sugar moiety is in close 
proximity to the isoalloxazine ring of FAD. The anomeric carbon of the sugar moiety is 
located at a distance of 8.0 Å in both the monomers for kpUGMox and the corresponding 
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distance in drUGMox is 3.3 Å which is consistent with the predictions from modeling 
studies.  
A      B 
 
 
 
 
 
 
C      D 
 
 
 
 
 
 
 
 
Figure 4-12 Comparison of drUGM and kpUGM substrate complex structures. A) Over 
lay of drUGMox (blue) and kpUGMox (red). Note the fully closed conformation of the 
mobile loop 1and 2 in drUGMox. B) Overaly of drUGMox and kpUGMox to highlight the 
binding mode differences of UDP-Galp. The sugar moiety is orieted close to FAD in 
drUGMox, while in kpUGMox it is away from the FAD. Also, note the distance between 
the anomeric carbon of galactose in drUGMox and kpUGMox. C) Overlay of drUGMred 
(Green) and kpUGMred (cyan). The mobile loop 2 adopt similar conformation both the 
complexes, however, mobile loop 1 is missing in the kpUGMred (poor density in this 
region). The binding mode of UDP-Galp is similar in both the complexes. D) Overlay of 
drUGMred (Green) and kpUGMred (cyan) to highlight the puckering of the isoalloxazine 
ring of FAD. In kpUGMred the N5 is pointing towards the protein, while, in drUGMred the 
N5 atom of FAD is puckered towards the substrate.  
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The binding mode of UDP-Galp in drUGMred and kpUGMred (monomer B) is 
similar and the interaction patterns of the substrate were identical in both the complexes 
(Figure 4-12). In kpUGMred monomer A has UDP (not UDP-Galp) in the active site and 
its binding mode is significantly different from the UDP portion of the substrate in 
monomer B. The mobile loop of kpUGMred (monomer A) is not in a fully closed 
conformation, when compared with the mobile loop of monomer B. The phosphate 
groups of UDP in monomer A are not stabilized by the two conserved arginines (Arg174 
and Arg280). In drUGMred, a fully closed conformation is observed in all the chains and 
the two conserved arginines (Arg198 and Arg305) stabilize the phosphate groups of 
UDP-Galp. Also, differences in FAD conformation were observed between kpUGMred 
and drUGMred. In both complexes the isoalloxazine ring of reduced FAD exist in a bent 
conformation, but the orientation of N5 of isoalloxazine ring was found to be different 
between the two complexes. In kpUGMred, N5 is pointing towards backbone carbonyl 
oxygen of Pro59 and the distance between N5 of FAD to the anomeric carbon is 3.6 Å 
(monomer B). In drUGMred, N5 of reduced FAD is orient towards the substrate (re-face) 
and distance between the N5 of reduced FAD and the anomeric carbon is 2.8 Å. Based on 
these differences, drUGMred can be considered as a closer approximation for reduced 
UGM:substrate complex. 
4.8 Structure of drUGM:UDP complex 
 
Crystals of drUGM:UDP complexes were grown by the microbatch method using 
conditions similar to drUGMox. drUGM:UDP complex crystallized in the P212121 space 
group and the unit cell dimensions were similar to drUGM:substrate complex structures. 
Crystals of drUGM:UDP complex diffracted to 2.5 Å and the structure was determined 
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by the MR method. drUGMox was used as the search model for MR using MOLREP 
(Vagin & Teplyakov, 2000). Data collection and refinement statistics are shown in Table 
4-3. The asu of the drUGM:UDP crystal contains 5 homodimers (Partha et al, 2009).  
A       B 
 
 
 
 
 
 
 
Figure 4-13 Structure of drUGM:UDP complex. A) Ribbon diagram representation of 
the overall structure of drUGM:UDP. The simulated annealing omit maps (contoured to 
2.0 σ) for FAD and UDP were shown as green mesh. FAD and UDP were modeled into 
the density. The two mobile loops exist in a closed conformation. B) Binding mode of 
UDP. Active site interactions of UDP is comparable to the interactions of UDP moiety in 
drUGM:substrate complexes. The sugar binding region is occupied by a water molecule 
(red sphere).  
 
The overall structure of drUGM:UDP complex is similar to drUGMox and 
drUGMred including the conformation of two flexible loops (0.54 Å and 1.0 Å rmsd for 
drUGMox and drUGMred respectively). UDP is entirely buried in the active site and is 
folded in a conformation similar to the UDP portion of the substrate. The active site 
interactions of UDP are similar to the UDP moiety of the substrate found in the drUGMox 
and drUGMred (Figure 4-13). The sugar binding region is occupied by a water molecule. 
Binding of UDP in the closed conformation of drUGM indicates that active site closure is 
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driven by interactions with the UDP portion of the substrate, which is consistent with 
previous studies. 
4.9 Structure of drUGM:UMP complex 
The structure of drUGM:UMP complex was determined in order to understand 
the role of β-phosphate in UDP and its effect on loop movement and the active site 
interactions. 
A                 C 
  
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure 4-14 Structure of drUGM:UMP complex. A) Simulated annealing omit maps 
(contoured to 2.0 σ) with UMP and FAD modeled into the density. B) Active site 
interactions of UMP is similar to the UMP portion of UDP from drUGM:UDP complex. 
Arg305 is located away from the phosphate group of UMP. C) Interactions of UMP in 
chain B. Arg305 is oriented close to the phosphate group of UMP. 
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crystals were grown by the microbatch method and crystallized in the P212121 space 
group. Crystals of drUGM:UMP complexes diffracted to 2.8 Å and the unit cell 
dimensions were similar to the drUGM:UDP complex. The structure of the drUGM:UMP 
complex was determined by using drUGMox (after removal of ligands) as the starting 
model for refinement. Data collection and refinement statistics are shown in Table 4-5. 
The asu has 5 homodimers and the overall structure is similar to the drUGM:UDP 
complex structure.  
 
Table 4-5 Data collection statistics and refinement for drUGM:UMP complex. 
 
 
  
drUGM:UMP 
 
Data collection 
 
Space group P212121 
Cell dimensions    
    a, b, c (Å) 137.8, 175.9, 222.0 
 90.00, 90.00, 90.00 
Resolution (Å) 2.80 (2.90-2.80) 
Rsym  19.2 (54.6) 
I / σI 5.6 (2.5) 
Completeness (%) 100 (100) 
Redundancy 7.5  
 
 
Refinement  
Resolution (Å) 30.0-2.8 
No. reflections 964991  
Rwork / Rfree 0.21/0.27 
No. atoms  
    Protein 29763 
    Ligand (FAD and UMP) 740 
    Water (molecules) 88 
B-factors  
    Protein 58.0 
    Ligand 67.4 (UMP) 
62.3  (FAD)                          
 
    Water 48.9 
r.m.s. deviations  
    Bond lengths (Å) 0.007 
    Bond angles (°) 
 
1.1 
*values in the parenthesis are for the highest resolution shell 
 85 
The simulated annealing difference map revealed electron density for FAD and 
UMP (Figure 4-14). The two mobile loops exist in the closed conformation. Arg198 of 
the mobile loop stabilizes the phosphate group of UMP, but Arg305 is located away from 
the phosphate group (Figure 4-14). Minor differences in the side chain orientations for 
Arg198 and Arg305 were observed in chain B of drUGM:UMP complex. In chain B, 
Arg305 is oriented towards the phosphate group of UMP (Figure 4-14). The side chain of 
Arg198 showed a different orientation but is able to stabilize the phosphate group of 
UMP. The significance of these differences in arginine side chain orientation (in chain B) 
is not clear at this moment. 
4.10 Structure of drUGM:UDP-Glc complex 
Despite the structural similarity between UDP-Galp and UDP-Glc, the latter is 
neither a substrate nor an inhibitor for UGM and binds very poorly (Kd = 750 µM for 
reduced kpUGM) (Gruber et al, 2009a). The structure of drUGM:UDP-Glc complex was 
determined with the aim of understanding its binding mode, active site interactions (C4 
hydroxyl group), effect on  mobile loop movement and correlate this structural 
information with the observed activity of UDP-Glc. Crystals of drUGM:UDP-Glc 
complex were grown by microbatch using conditions similar to drUGM:substrate 
complexes. The space group and unit cell dimensions of drUGM:UDP-Glc complex were 
similar to the drUGM:substrate complex crystals. Crystals of drUGM:UDP-Glc complex 
diffracted to 2.5 Å. The structure of drUGM:UDP-Glc was determined by using 
drUGMox (ligands removed) as the starting model for refinement. Data collection and 
refinement statistics for drUGM:UDP-Glc complex shown in Table 4-6. The asu has 5 
homodimers and the overall structure is similar to drUGM:substrate complex structure. 
 86 
The simulated annealing difference map reveled electron density for FAD and nucleotide 
portion (UDP) of UDP-Glc. The density for the UDP portion (of UDP-Glc) was well 
defined in all the monomers. Further rounds of model building and refinement showed 
improvement in density (Figure 4-15) for the sugar moiety in chain D as compared to 
other chains (poor density in other chains). Hence, UDP-Glc was modeled only in chain 
D and further rounds of refinement were carried out. The overall structure of 
drUGM:UDP-Glc complex is similar to drUGM:substrate complex structures, including  
Table 4-6 Data collection and refinement statistics for drUGM:UDP-Glc complex. 
 
 
  
drUGM:UDP-Glc 
 
Data collection 
 
Space group P212121 
Cell dimensions    
    a, b, c (Å) 137.8, 175.9, 222.0 
 90.00, 90.00, 90.00 
Resolution (Å) 2.50 (2.59-2.50) 
Rsym  16.7 (59.9) 
I / σI 5.2 (2.0) 
Completeness (%) 96.6 (80.0) 
Redundancy 7.4  
 
 
Refinement  
Resolution (Å) 20-2.5 
No. reflections 189638 
Rwork / Rfree 0.21/0.27 
No. atoms  
    Protein 30186 
    Ligand (FAD, UDP and 
UDP-Glc) 
791 
    Water (molecules) 525 
B-factors  
    Protein 54.4 
    Ligand 62.8 (UDP-Glc) 
58.6 (UDP)  
58.0 (FAD)                          
 
    Water 52.3 
r.m.s. deviations  
    Bond lengths (Å) 0.008 
    Bond angles (°) 
 
1.2 
*values in the parenthesis are for the highest resolution shell 
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Figure 4-15 Structure of drUGM:UDP-Glc complex. A) Simulated annealing omit map 
(contoured to 2.0 σ) for UDP-Glc in chain D of drUGM:UDP-Glc complex. UDP-Glc 
modeled into the density. B) 2Fo-Fc map (contoured to 1.0 σ) of UDP-Glc after 
refinement. C) Overlay of drUGMox (green) and UDP-Glc complex (blue). The overall 
structure of drUGM:UDP-Glc is similar to drUGMox including the two mobile loops. 
Note the differences in the orientation of sugar moiety in drUGMox and drUGM:UDP-Glc 
complex. D) Active site interactions of UDP-Glc.  
R305
W184
T180
R198 Y179
F176
Y370 Y209
H109
N296
Y305
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the conformation of the two mobile loops. However, the binding mode of UDP-Glc is 
significantly different when compared to the binding mode of UDP-Galp. 
4.11 Comparison of drUGM-Glc and drUGM:UDP-Galp complex structures 
A detailed comparison of drUGM:UDP-Glc complex structure with 
drUGM:UDP-Galp structures revealed key differences in the binding mode and active 
site interactions (Figure 4-16). The binding mode of UDP-Glc is significantly different 
from the binding mode of UDP-Galp except in the uridine binding region. Stacking 
interactions for the uracil base and the hydrogen bonding pattern of the ribose moiety 
were similar in drUGM:substrate structures and the UDP-Glc complex structure (Figure 
4-15). The orientations of the two phosphate groups in UDP-Glc are considerably 
different than the phosphate groups of UDP-Galp (Figure 4-16). The phosphate groups of 
the UDP-Galp (in drUGM:UDP-Galp structures) are in close contact with the conserved 
arginines (Arg198 and Arg305). In the drUGM:UDP-Glc complex structure, Arg198 is in 
close contact with the α-phosphate group of UDP-Glc, but Arg305 is oriented towards 
the sugar moiety of UDP-Glc. The side chain of Arg305 is tilted at an angle of ~ 45o as 
compared to its orientation in the substrate complex structure. This could result in poor or 
weak stabilization of the β-phosphate of UDP-Glc by Arg305. Furthermore, the anomeric 
carbon of galactose moiety in drUGMred is located at a distance of 2.80 Å from N5 of 
reduced FAD (a productive distance) (Figure 4-15) to form FAD-galactosyl adduct. The 
corresponding distance for glucose in drUGM:UDP-Glc complex is 5.8 Å (a non-
productive distance). The orientation of the glucose moiety is significantly different 
compared to the galactose moiety of the substrate complex structures. In the 
drUGM:UDP-Glc complex, the C2 hydroxyl group (of glucose) forms a hydrogen bond 
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with the side chain of Tyr335 and the C3 hydroxyl group is located at a distance of 2.8 Å 
from N5 of FAD (Figure 4-15). The C4 hydroxyl group is located at a distance of 3.3 Å 
from O4 of FAD and its equatorial orientation results in weak hydrogen bond interactions 
 
A        B 
 
 
 
 
 
 
 
Figure 4-16 Comparison of the diphosphate interactions of drUGMox and drUGM:UDP-
Glc. A) In drUGMox the two phosphate groups of UDP-Galp are stabilized by Arg198 
and Arg305. B) In drUGM:UDP-Glc complex the side chain Arg305 is tilted and is not in 
close contact with the β-phosphate of UDP-Glc, however, Arg198 is able to interact with 
the α-phosphate of UDP-Glc. Also, note the orientation of the glucose moiety as 
compared to the galactose moiety in A.  
 
with O4 of FAD. In addition, the C4 hydroxyl of glucose orients towards Phe210 and 
Tyr209, an unfavorable hydrophobic environment. The C6 hydroxyl group of glucose 
forms weak hydrogen bond interactions with His109 and this interaction was also 
observed substrate complex structure.  The altered binding mode and interaction pattern 
of UDP-Glc provide a basis for the observed differences in the recognition between 
UDP-Glc and UDP-Galp. These structural observations provide a basis for the inability 
of UDP-Glc to act as a substrate or inhibitor for UGM.  
R305
R198
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4.12 Comparison of drUGM:UDP-Glc with kpUGM:UDP-Glc complex structure 
During the progress of our structural investigations on drUGM, the structure of 
kpUGM in complex with UDP-Glc was reported (Gruber et al, 2009a). Comparison of   
A          B 
 
 
 
 
 
 
 
Figure 4-17 Comparison of drUGM:UDP-Glc and kpUGM:UDP-Glc complex. A) 
Overaly of drUGM:UDP-Glc (blue) and kpUGM:UDP-Glc (red) structures. The binding 
of the UDP-Glc is similar in both the structures. The conserved arginines show 
differences in their interaction pattern with the phosphate groups of the UDP-Glc. Note 
the orientations of Arg198 vs Arg174 and Arg305 vs Arg280. B) Overlay of the 
monomer B of kpUGM:UDP-Glc with drUGM:UMP complex. Monomer B of 
kpUGM:UDP-Glc has only UMP bound to it and hence we compared this with 
drUGM:UMP complex. The alignment suggests that UMP is bound in a different 
conformation and location in kpUGM as compared to the binding mode of UMP in 
drUGM. 
 
drUGM:UDP-Glc and kpUGM:UDP-Glc complex structures revealed significant 
differences between them. The overall structures of drUGM:UDP-Glc and kpUGM:UDP-
Glc are similar, but differences in active site interactions and mobile loop conformations 
were observed (Figure 4-17). The mobile loops in kpUGM:UDP-Glc exist in a different 
conformation (partially closed) compared to the fully closed conformation observed in 
drUGM:UDP-Glc complex structure. As a result, stabilization of α-phosphate of UDP-
Glc by Arg174 is weak compared to the close contact maintained by the corresponding 
R198
R198
R305
R305
R174 R174
R280
R280
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residue (Arg198) in drUGM:UDP-Glc complex. The binding mode of UDP-Glc in 
kpUGM and in drUGM is similar. The active site Arg280 (in kpUGM) is located away 
from the β-phosphate of UDP-Glc and orients towards the sugar moiety (close to C6 
hydoxyl group of glucose). The corresponding residue in drUGM (Arg305) is also 
oriented towards the sugar moiety, but not close to C6 hydroxyl group of glucose. The 
Arg305 side chain is tilted slightly and is able to make contacts with the β-phosphate of 
UDP-Glc. The mobile loops in drUGM:UDP-Glc complex exist in a closed conformation 
(in all chains). UDP moiety was modelled  in chains that did not show density for sugar 
moiety. In those chains that were modeled with UDP, the interaction pattern is similar to 
UDP bound structure (drUGM:UDP complex). In kpUGM:UDP-Glc complex, the active 
site of monomer A and monomer B contains UDP-Glc and UMP respectively. The 
mobile loop of monomer B exists in an open conformation and the interaction of UMP is 
significantly different from the UMP portion of UDP-Glc bound to monomer B. The 
binding mode of UMP (monomer B) is also significantly different from the binding mode 
of UMP observed in our drUGM:UMP complex structure. For example, the phosphate 
moiety of UMP is not in close contact with the conserved arginines (Arg174 and Arg284 
in kpUGM) compared to the close contacts maintained by Arg198 and Arg305 in 
drUGM:UMP complex. The differences in the mobile loop conformation between 
drUGM:UDP-Glc and kpUGM:UDP-Glc complexes may be explained on the basis of the 
method of crystallization used to form the complex (Gruber et al, 2009a). The 
kpUGM:UDP-Glc complex crystals were obtained by soaking. UDP-Glc was soaked into 
preformed unliganded kpUGM crystals. drUGM:UDP-Glc complex was crystallized by 
cocrystallization method. It is well known that conformational changes may not be 
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apparent in soaking methods (Hassell et al, 2007). In such cases there is a need to cross 
validate the structures by forming the protein-ligand complexes by cocrystallization 
methods. This is evident from the structures of kpUGM:UDP-Glc and drUGM:UDP-Glc 
obtained by different crystallization methods.  
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CHAPTER 5 
 
Evaluation of UGM inhibitors 
5.0 Ligand-based approach: Phosphonate analog of UDP-Galp (GCP) 
Inhibitors of enzymes that mimic the structure of natural substrate are called 
substrate analogs. They will not undergo any turnover upon binding to the enzyme and 
inhibit the reaction (except suicide inhibitors). Substrate analogs are examples of ligand-
based design. GCP is a phosphonate analogue of UDP-Galp with the anomeric (Figure 5-
1) oxygen replaced by a methylene functionality. The rationale behind the design of GCP 
is based on the previous mechanistic investigations reported for UGM (Barlow et al, 
1999; Fullerton et al, 2003; Huang et al, 2003; Soltero-Higgin et al, 2004). It has been 
proposed that the C-O anomeric bond of UDP-Galp is cleaved during the reaction with 
the formation of an FAD-galactosyl adduct and UDP (a good leaving group) (See section 
1.3, Figure 1-5 and 1-6). The substitution of a carbon atom for the anomeric oxygen (as 
in GCP) would form a C-glycosidic linkage that cannot be cleaved during the reaction 
and therefore GCP would be expected to act as an inhibitor of UGM.  
A      B 
 
 
 
 
Figure 5-1 Design of phosphonate analog as inhibitor of UGM. A) Structure of UDP-
Galp 1 to illustrate the design of its phosphonate analog. The anomeric oxygen is 
highlighted by blue circle. B) The phosphonate analog of UDP-Galp (GCP) is designed 
by replacing the anomeric oxygen by the methylene group (blue circle) at the anomeric 
position. The phosphonate analog is expected not to be cleaved but inhibit UGM.  
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Replacing an oxygen atom with a methylene moiety is considered as an isosteric 
replacement, and has been used widely in medicinal and biological chemistry to probe 
phosphoryl transfer processes (Engel, 1977; Romanenko & Kukhar, 2006). X-ray 
analyses of phosphonates show that the bond angles and bond lengths are within 10 % of 
the natural substrates (Engel, 1977).  
Previously, synthesis and activity measurement of GCP and  UDP-1C-Galf 
(phosphonate analog of UDP-Galf)  towards E. coli UGM (ecUGM) has been reported 
(Caravano & Vincent, 2009). The inhibitory activity of GCP and UDP-1C-Galf were 
determined for reduced and oxidized ecUGM. GCP and UDP-1C-Galf showed <10 % 
inhibition under reducing conditions. GCP and UDP-1C-Galf displayed 38 % and 91 % 
inhibition under non-reducing conditions respectively. The concentration of substrate 
(UDP-Galf) used in the evaluation of GCP and UDP-C-Galf was set to 1 mM which is  
much higher than the Km of UDP-Galf (27 µM) for ecUGM (Caravano & Vincent, 2009; 
Zhang & Liu, 2000). This would make proper evaluation of weak inhibitors difficult. 
5.1 Inhibitory activity of GCP 
To gain insights on the inhibitory activity and binding, GCP was evaluated 
against drUGM, kpUGM and mtUGM. GCP showed greater than 50% inhibition against 
all three UGMs, when used at 1 mM (all inhibition studies were performed under 
reducing conditions). The inhibitory activity of GCP was further evaluated at different 
concentrations to determine the IC50 values against drUGM, kpUGM and mtUGM (Table 
5-1). The IC50 values of GCP against various UGMs suggest that GCP is a weak inhibitor 
of UGM.  
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Table 5-1 Inhibitory activity of GCP towards kpUGM, mtUGM and drUGM. 
Enzyme    IC50 (µM)* 
kpUGM    479 ± 34 
mtUGM    495 ± 38 
drUGM    411 ± 13 
*The errors represent the standard deviation based on duplicate measurements 
5.2 Structure of drUGM:GCP complex 
In order to determine the binding mode and active site interactions of GCP, the  
UGM:GCP complex structure was determined. The substrate binding mode in drUGM is 
similar to the kpUGM:UDP-Galp reduced complex structure (Gruber et al, 2009b) and 
the inhibition profile of GCP towards drUGM, kpUGM and mtUGM are similar. Also, I 
had high success rate in forming ligand complexes using drUGM. Therefore, I decided to 
use drUGM to understand GCP binding and its active site interactions. The structure of 
the drUGM:GCP complex is the first report of a complex structure of a phosphonate 
analog of UDP-Galp bound to an enzyme (PDB code 3MJ4). The drUGM:GCP complex 
was crystallized by the microbatch method and the crystals diffracted to 2.6 Å. The unit 
cell dimensions and space group of drUGM:GCP complex were similar to 
drUGM:substrate complex crystals. Data collection and refinement statistics are shown in 
Table 5-2. The drUGM:GCP structure determined by using drUGMox (without ligands) as 
the starting model for refinement.  The simulated annealing difference map revealed well 
defined density for the ligands (FAD and GCP). But, the density for GCP is complete 
only in chain D (Figure 5-2). Hence, GCP was modeled only in chain D. In other chains 
the density for sugar moiety was weak and we modeled UDP in those chains. The overall 
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structure of the drUGM:GCP complex (including the two mobile loops) is similar to the 
drUGM:UDP-Galp complex structures (Figure 5-3). The rmsd between the 
drUGM:UDP-Galp complex and the drUGM:GCP complex is 0.4 Å for all  equivalent 
Cα atoms. Based on the structural similarity (between UDP-Galp and GCP), it is 
anticipated that the binding mode of GCP would be similar to UDP-Galp. However,  
 
Table 5-2 Data collection and refinement statistics for drUGM:GCP complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*values in the parenthesis are for the highest resolution shell 
 
 
Data collection 
 
drUGM:GCP complex  
 
Space group P212121 
Cell dimensions   134.1, 175.6, 223.9 
    a, b, c (Å) 90.00, 90.00, 90.00 
  
Resolution (Å) 2.65 (2.74-2.65) 
Rsym   14.9 (57.8) 
I / σI 6.6  (2.0) 
Completeness (%) 100  (100) 
Redundancy 7.1 (7.0)  
 
 
Refinement  
Resolution (Å) 44.5-2.65 
No. reflections 162540 
Rwork / Rfree 0.20/0.26 
No. atoms  
    Protein 29702 
    Ligands  755 
    Water (molecules) 613 
B-factors  
    Protein 53.3 
    Ligand 62.6 
                            
    Water 45.3 
r.m.s. deviations  
    Bond lengths (Å) 0.008 
    Bond angles (°) 
 
1.2 
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A       B 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2 Electron density maps of GCP in drUGM:GCP complex structures. A) The 
omit map of GCP in chain D (contoured to 2.0 σ) after simulated annealing refinement. 
GCP molded into the density after simulated annealing refinement. B) The 2Fo-Fc map of 
GCP (contoured to 1.0 σ ) in chain D after refinement.  
 
differences in the binding mode and active site interactions were observed for GCP. GCP 
is bound in a different folded conformation (Figure 5-3) as compared to the U-shaped 
conformation of UDP-Galp observed in the substrate complex structures (Partha et al, 
2009). The interactions of GCP at the uridine binding region (Figure 5-3) were similar to 
the uridine moiety of UDP-Galp in drUGM:UDP-Galp structures. Notable differences 
were observed in the diphosphate and sugar binding regions. The β-phosphate group of 
GCP is bent on top of the uridine, resulting in significant alterations in the orientation of 
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the sugar moiety and the interaction patterns of the β-phosphate group (Figure 5-3). In 
the overlaid structures of GCP (from drUGM:GCP complex) and UDP-Galp (from 
drUGM:UDP-Galp complex) the distance between the phosphorous atom of α-phosphate 
and β-phosphate group in GCP to the corresponding atoms of UDP-Galp  
 
A          B 
 
 
 
 
 
 
C        D  
 
 
 
 
 
 
 
Figure 5-3 Overall structure of drUGM:GCP complex and the active site interactions. A) 
Overlay of drUGM:GCP (Red) and drUGM:UDP-Galp (Blue) structures. B) Interactions 
of the uridine moiety of GCP in drUGM:GCP structure. C) Orientation of the α-
phosphate and β-phosphono groups of GCP and their interactions with R305 and R198. 
D) Interactions of the two phosphate groups of UDP-Galp with R305 and R198. Note the 
distance between the anomeric oxygen and NH1/NH2 of Arg305. 
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A       B 
 
 
 
 
 
 
 
 
C       D 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4 Orientation of the conserved arginines and the sugar moiety in drUGM:GCP 
complex. A) Overlay of drUGM:GCP (Carbon, gray) and drUGM:UDP-Galp (Carbon, 
yellow) structures to highlight the orientation of the two active site arginines (R305 and 
R198). The alignment also reveals the differences in the sugar orientation between the 
two complex structures. B) Alignment of bound conformation of GCP (Carbon, yellow) 
from drUGM:GCP complex and UDP-Galp (Carbon, gray) from drUGM:UDP-Galp 
complex to emphasize that the sugar moiety is able to maintain the 4C1 conformation in  
both the complexes. C) Interactions of the sugar moiety of GCP in drUGM:GCP 
complex. D) Overlay of drUGM:GCP (Carbon, yellow) and drUGM: UDP-Galp (Carbon, 
gray) structures to highlight the differences in the side chain orientation of Arg364 and 
Tyr370. 
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was found to be 1.1 Å and 2.5 Å respectively. In addition, the distance between the 
phosphorus atom of β-phosphate (in UDP-Galp) and the uracil ring was 7.1 Å in the 
drUGM:UDP-Galp complex. The corresponding distance for GCP in the drUGM:GCP 
complex was 5.0 Å. These measurements clearly indicate that the β-phosphate group of 
GCP undergoes significant conformational changes upon binding to UGM. Structural and 
biochemical studies revealed the role of two conserved active site arginines that stabilize 
the two phosphate groups of the UDP-Galp. A closer look at the interactions of β-
phosphate in drUGM:UDP-Galp complex structure revealed that the anomeric oxygen 
atom is located at a distance of 2.8 Å and 3.0 Å  from NH1 and NH2 of Arg305 
respectively (Figure 5-3). In GCP, the anomeric oxygen is substituted with a methylene 
group that could extend the bond lengths and alter the bond angles (by up to 10 %) and 
would reduce the electronegativity at that position. In the drUGM:GCP structure, the side 
chain of Arg305 adopts a folded conformation as compared to the extended orientation of 
Arg305 side chain observed in the drUGM:UDP-Galp structure. The CD-NE-NE-CZ 
fragment of Arg305 in drUGM:GCP is tilted ~ 45o to the corresponding fragment in 
drUGM:UDP-Galp complex. This orientation would avoid any steric clashes with the 
methylene group of GCP (Figure 5-4). The rearrangement of Arg305 side chain and the 
bent conformation of the β-phosphate group of GCP could be due to unfavorable steric 
interactions between the methylene group and the side chain of Arg305. The α-phosphate 
group of GCP showed only subtle changes in its geometry and is located at a stabilizing 
distance from Arg198 (Figure 5-3). The NH1 and NH2 of Arg198 is tilted at a different 
angle when compared with the drUGM:substrate complex structure. In drUGM:UDP-
Galp complex structure, Arg198 stabilizes the α-phosphate group of UDP-Galp and is 
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also in close contact with the one of the oxygen atoms of β-phosphate group (Figure 5-3). 
In the drUGM:GCP structure the bent geometry of the β-phosphate group result in the 
loss of additional stabilization by Arg198. 
It is possible that any distortion of the β-phosphate group would alter the binding 
mode of the hexose ring. As expected, the galactose moiety of GCP is oriented in a 
different fashion and the interactions (Figure 5-4) are different compared to the galactose 
portion of the substrate in the drUGM:substrate structure (Partha et al, 2009). The sugar 
moiety is able to maintain the 4C1 conformation (Figure 5-4). In the drUGM:GCP 
structure, the C2 hydroxyl group (of galactose) is oriented close to the side chain of 
Arg305 and the C3 hydroxyl group forms a hydrogen bond with the N5 of FAD. The 
corresponding hydroxyl groups of galactose in the drUGM:UDP-Galp complex form 
water mediated hydrogen bonds with His88, Asn372, Arg364 and Tyr371 (Partha et al, 
2009). The C6 hydroxyl group of GCP forms hydrogen bonds with the side chains of 
Asn372, Tyr370 and Arg198. In UDP-Galp (from the drUGM:UDP-Galp structure) the 
C6 hydroxyl group forms a hydrogen bond with His109. The C4 hydroxyl group of GCP 
forms a hydrogen bond with the O4 of FAD and this interaction is also observed in the 
drUGM:UDP-Galp complex structures.  
The drUGM:GCP complex structure reveals other conformational changes when 
compared to the drUGM:UDP-Galp structures. The side chains of Arg364 and Tyr370 
are oriented towards the substrate binding pocket in the drUGM:UDP-Galp structure, 
whereas, in the drUGM:GCP structure the side chains of Arg364 and Try371 are in close 
contact with the phosphate group of FAD and N10 of FAD respectively (Figure 5-4). The 
binding mode and interactions of GCP in the drUGM:GCP complex structure suggest that 
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subtle isosteric changes in the ligand structure can result in significant alterations in its 
binding mode with UGM. 
5.3 Comparison of the binding mode of GCP with other sugar nucleotide   
      phosphonates 
 
There are few other reported structures of enzymes complexed with sugar 
nucleotide phosphonates (Clarke et al, 2008; Gordon et al, 2006). The crystal structures 
of UDP-N-acetylglucosamine (UDP-GlcNAc) and the corresponding phosphonate 
analog, (UDP-1C-GlcNAc) in complex with rabbit N-acetylglucosaminyltransferase 1 
(GnT1) show no differences in the binding mode of the phosphonate analog compared to 
the natural substrate (PDB code, 2APC). The Ki of the phosphonate analog towards GnT1 
was found to be 28 µM, consistent with a similar binding mode to the natural substrate 
(Km = 78 µM). Analysis of the active site interactions of GnT1 with the natural substrate 
revealed that the hydroxyl of Ser322 forms a hydrogen bond with the anomeric oxygen, 
whereas in the phosphonate complex, this interaction is missing and the hydroxyl group 
rotates away to form a hydrogen bond with backbone NH of Ser322. The active site 
architecture of GnT1 does not discriminate between the isosteric changes to ligand 
structure (oxygen vs. methylene), resulting in identical binding modes for substrate and 
the phosphonate analog. 
The other sugar nucleotide phosphonate structure is the complex between the C-1 
phosphonate analog of UDP-GlcNAc and O-linked GlcNAc transferase (OGT) which is 
involved in the post-translational modification of proteins (PDB code 2JLB). This 
phosphonate analog is a poor inhibitor of OGT, IC50 > 5 mM (Km for natural substrate is 
0.5 µM) (Hajduch et al, 2008). The poor inhibitory activity of this compound was 
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attributed to the rigid active site architecture of OGT that is able to discriminate between 
the change in geometry of O-glycosidic bond and the C-glycosidic bond. However, 
 
A      B 
 
 
 
 
 
 
Figure 5-5 Overlay of binding conformation GCP (from drUGM:GCP complex) with 
UDP-1C-GlcNAc. A) Alignment of GCP (Carbon, yellow) and UDP-1C-GlcNAc 
(Carbon, gray) from GnT1 (PDB code 2APC). B) Alignment of GCP (Carbon, yellow) 
and UDP-1C-GlcNAc (Carbon, gray) from OGT (PDB code 2JLB). The urdine portion of 
GCP and UDP-1C-GlcNAC aligns well (A and B) compared to the diphosphate and 
sugar region of the molecule. Note the proximity of β-phosphate group of GCP to the 
uracil ring, such an orientation not observed for UDP-1C-GlcNAc in A and B.  
 
structural and site-directed mutagenesis studies suggest that the phosphonate analog binds 
in a similar mode to the natural substrate (Clarke et al, 2008), although the crystal 
structure of OGT complexed with UDP-GlcNAc has not been published. 
Alignment of GCP with the phosphonates from 2APC and 2JLB was performed 
(Figure 5-5) to examine the differences in the binding mode of GCP and the phosphonate 
analog of UDP-GlcNAc. The uridine portion of GCP and UDP-1C-GlcNAc (in 2APC 
and 2JLB) aligned well, but the diphosphate and hexose portions of the molecule adopt 
vastly different orientations. This comparison reveals that GCP adopt a novel binding 
conformation not observed in the X-ray crystallographic analysis of the phosphono 
analogues of UDP-GlcNAc complexed with either GnT1 or OGT. 
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The weak IC50 values of GCP can be explained on the basis of the observed 
structural reorganization in the active site that occurs upon binding of GCP and an 
associated loss of favorable interactions, including the stabilization of the two phosphate 
groups of GCP by the conserved arginines. A similar binding mode and interaction 
pattern may account for the poor inhibitory activity of GCP and UDP-C-Galf towards 
ecUGM (Caravano & Vincent, 2009). The drUGM:GCP complex structures provided a 
structural basis to understand the interactions of GCP at a molecular level and underline 
the consequence of replacing the anomeric oxygen of the substrate with a methylene 
functionality. Although, phosphonates are well established isosteric replacements for 
phosphate groups, the results from this study reveal that in some cases (for example, 
UGM) such isosteric modifications may not be applicable for inhibitor development. The 
structural results also illustrate one potential problem in using substrate analogues as 
probes for the binding of substrates to enzymes in some cases.  
5.4 Structure-based approach: Inhibitors from virtual screening 
In addition to ligand-based approaches, inhibitors for enzymes can be identified 
by structure-based methods, such as structure-based virtual screening (SBVS). If the 3-
dimensional structure of the enzyme is known, then screening of chemical libraries 
against the enzyme can be performed by SBVS (De Azevedo, 2010; Ghosh et al, 2006; 
Lyne, 2002; Mestres, 2002; Sousa et al, 2010; Xu, 2002). On the other hand, if the 
structure of the target protein is not available or is unknown, then a model of the protein 
can be prepared by homology modeling for SBVS. 
 SBVS involves docking (binding mode prediction) and scoring (ranking affinity) 
of a molecule (from a chemical database) into the binding site of the target protein 
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(Bissantz et al, 2000). SBVS is complementary to high-throughput screening (HTS) 
technique (Mestres, 2002) and has been proven to be successful in identifying inhibitors 
for various therapeutic targets (Lyne, 2002; Sousa et al, 2010; Villoutreix et al, 2009)  
(Table 5-3).  The flow chart for a typical SBVS is shown in Figure 5-6. Various docking  
Table 5-3 Examples for successful application of structure-based virtual screening.  
 
 Target     Method               Reference 
 
Carbonic anhydrase II   FlexX    (Grüneberg et al, 2002) 
Ptp1b      DOCK   (Doman et al, 2002) 
Estrogen receptor    PRO_LEADS  (Baxter et al, 2000) 
Thrombin     PRO_LEADS  (Baxter et al, 2000) 
Factor Xa     PRO_LEADS  (Baxter et al, 2000) 
Thymidylate synthase   DOCK   (Tondi et al, 1999) 
Retinoic acid receptor   ICM    (Schapira et al, 2000) 
Farnesyl transferase    EUDOC   (Perola et al, 2000) 
Kinesin     DOCK   (Hopkins et al, 2000) 
Hypoxanthine-guanine-xanthine  
phosphoribosyl tansferase   DOCK   (Aronov et al, 2000) 
DNA gyrase     LUDI    (Boehm et al, 2000) 
HIV-1 RNA transactivation  
response element    ICM    (Filikov et al, 2000) 
 
programs have been used for SBVS and they differ in their docking algorithm (binding 
mode prediction) and the scoring functions.  
A number of comparative studies have been reported to evaluate the performance 
of docking programs for virtual screening (Bissantz et al, 2000; Cummings et al, 2005; 
Kellenberger et al, 2004; Schneider & Böhm, 2002; Schulz-Gasch & Stahl, 2003; Seifert, 
2009; Smith et al, 2003; Stahl & Rarey, 2001; Warren et al, 2006; Wilton et al, 2003). 
FlexX (Kramer et al, 1999; Rarey et al, 1996; Stahl & Rarey, 2001) is one of the docking 
programs widely used in the SBVS and proven to be successful in identifying inhibitors 
for various drug targets (Cho et al, 2008; Grüneberg et al, 2002; Kiss et al, 2008; Miguet 
et al, 2009; Ramsden et al, 2009)  
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Figure 5-6 Flow chart for structure-based virtual screening of a chemical database. 
 
5.5 Application of SBVS to UGM 
Our collaborators (Professor Neil Thomas, Nottingham University) used FlexX 
(Rarey et al, 1996) docking program to perform SBVS. The crystal structure of kpUGM 
(Beis et al, 2005) was chosen as the target for SBVS. A structure of the UGM-substrate 
complex was not known at the time of performing these studies. The LeadQuest database 
(Tripos Inc.) was used as the virtual chemical library for identifying inhibitors. Based on 
the results from SBVS, 13 molecules (hits) were purchased and evaluated against various 
bacterial UGMs (Figure 5-7). The inhibition studies allowed me to identify some novel 
inhibitors that showed micromolar inhibition. These molecules can be considered as a 
starting point or lead molecule for further optimization to enhance their potency. The 
Starting database Starting target
Prepared database Prepared target
Molecular docking (FlexX , GOLD, 
DOCK etc) 
Analysis: Evaluate docked conformers and their scores 
Select compounds for assay 
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inhibition studies on UGM demonstrate the utility of SBVS as an alternative to HTS to 
identify novel enzyme inhibitors.     
5.6 Activity of inhibitors from virtual screening  
Hits that were identified through SBVS showed promising inhibitory activity 
towards kpUGM and mtUGM. Initially, inhibition studies were conducted by using 1 
mM of inhibitor in assays against kpUGM (Table 5-4). These results were later repeated 
against mtUGM. Compounds that showed > 80 % inhibitory activity at 1 mM were 
further screened at lower concentrations of the inhibitor. Due to limited availability of 
LQ6 and LQ10, they were not screened at 1 mM towards mtUGM. LQ6 and LQ10 
showed approximately 50 % inhibition at 1.0 µM (Table 5-5). LQ1 showed 84 % 
inhibition at 1 mM, but showed only 2 % inhibition at 10 µM against kpUGM. I am 
unable to screen LQ1 towards mtUGM at lower concentration (due to availability 
problems). The 13 compounds (Figure 5-7) that were chosen for evaluation can be 
classified into various structural classes, such as aminosugars, indole analogs, substituted 
amides, pyrimidine derivative, uridine analog, sugar phosphates, substituted sulfonamides 
and bridged-sugar analogs. The inhibition profile and the structure-activity relationship of 
each class of inhibitors are discussed in detail. 
5.6.1. Indole analogs 
As discussed previously (See section 4.3) the active site of UGM is divided into 
three regions, each with distinct binding regions, namely, uridine binding region, 
diphosphate binding region and the sugar binding region (Partha et al, 2009). LQ1, LQ6 
and LQ10 showed promising inhibitory activity towards kpUGM and mtUGM. Although 
LQ1 showed weak inhibition at lower concentrations, it has structural similarity to LQ6 
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 Figure 5-7 structures of the UGM inhibitors identified through virtual screening. 
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Table 5-4 Inhibition of UGM using 1 mM inhibitors.        
Compound     % inhibition  
kpUGM   mtUGM 
 
LQ1    84 (± 6)*    79 (± 1) 
LQ6    82 (± 1)         --  
LQ4    77 (± 1)    44 (± 3) 
LQ8    84 (± 2      53 (± 1) 
LQ10    86 (± 1)         -- 
SMC343   74 (± 2)    35 (± 2) 
RIR163   33 (± 2)               33 (± 2) 
RIR299   79 (± 1)               73 (± 4) 
RIR286   65 (± 1)               36 (± 4)  
ASK1    24 (± 3)               46 (± 3) 
ASK2    32 (± 3)               29 (± 2) 
ASK4    23 (± 3)               43 (± 4) 
ASK5 26 (± 5)               69 (± 2) 
-- not determined 
*
 The errors represent the standard deviation based on duplicate measurements 
 
 
Table 5-5 Inhibition of LQ6 and LQ10 towards kpUGM and mtUGM at 1 µM. 
      % inhibition 
 
                      kpUGM    mtUGM 
 
 
LQ6            52.0 (± 5) *     46 (± 2) 
 
LQ10            48 (± 1)        49 (± 2) 
 
*
 The errors represent the standard deviation based on duplicate measurements 
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and LQ10. All three compounds have an indole nucleus and we expected that the indole 
moiety may form stacking interactions with aromatic residues in the uridine binding 
region. Docking studies were carried out to predict the binding mode of these inhibitors. 
SURFLEX-DOCK (Tripos Inc) was used for docking. Coordinates of drUGM:substrate 
complex used for the docking (UDP-Galp removed from the active). The selection of the 
docked conformer is based on the stacking interactions with the aromatic residues 
(Tyr179 and Phe175) and also ability to make contacts with the conserved arginines 
(Arg198 and Arg305).  In the docked conformation of LQ1 and LQ10 the indole moiety 
is stacked between two aromatic residues (Tyr179 and Phe175) in the uridine binding 
region (Figure 5-8). The hydrazine moiety and the carbonyl group next to the hydrazine 
(in LQ1 and LQ10) are in close contact with the side chain of Arg198 (diphosphate 
binding region). The propyl chain does not show any specific interactions. The carbonyl 
group that connects the indole ring and the piperidine moiety forms a hydrogen bond with 
the side chain Trp184 (indole NH). The NH of indole moiety in LQ1 and LQ10 also form 
hydrogen bonds with side chain of Thr180. LQ6, a closely related molecule to LQ1 and 
LQ10 showed two different binding modes that are significantly different from LQ1 and 
LQ10 (Figure 5-8). The two binding modes (BM1 and BM2) did not show any stacking 
interactions between the indole moiety of LQ6 and Tyr179/ Phe175. In BM1, the indole 
moiety is stacked in between the isoalloxazine ring of FAD and the side chain of Arg198. 
The piperidine ring occupies the uridine binding region. The ether linkage attached to the 
piperidine ring folds on top of the indole moiety. In BM2, the piperidine ring occupies 
the sugar binding region, and the indole moiety is positioned at the entrance of the active 
site. The ether chain oriented towards the uridine binding region. The differences in the  
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Figure 5-8 Binding mode of indole analogs. Active site interactions of A) LQ1, B) 
LQ10, C) LQ6- binding mode 1 and D) LQ6-binding mode 2.  
 
 
binding mode of LQ6 compared to LQ1 and LQ10 are likely due to the spiro-type linkage 
at C4 of piperidine ring and increase in the length of ether chain.  
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5.6.2. Substituted amide (LQ4) and pyrimidine derivative (LQ8)  
LQ4 and LQ8 showed better inhibition against kpUGM than against mtUGM. The 
basis of this selectivity is not clear. Unfortunately, inhibition of kpUGM by LQ4 and 
LQ8 were poor at lower concentrations. Nevertheless, the inhibition results of these two 
inhibitors suggest that it may be possible to design inhibitors specific to one particular 
UGM homologue.  
5.6.3. Amino-sugar 
The amino-sugar, SMC343 showed better inhibition against kpUGM, but poor 
inhibition at lower concentrations. The lack of groups that could interact at the 
diphosphate binding region and the uridine binding region may account for the poor 
inhibition at lower concentrations. Sugar-mimetics like SMC343 may occupy the sugar 
binding region where the majority of the interactions are through water molecules and not 
through direct interaction with the amino acid residues. The potency of these inhibitors 
could be optimized by incorporating groups that can interact with the residues at the 
diphosphate and uridine binding regions.  
5.6.4. Uridine analog 
ASK5 is a bis-uridine analog, which could potentially occupy the uridine-binding 
region of the active site. This compound showed poor inhibition against kpUGM and 
moderate inhibition against mtUGM. The presence of two uridine units in this compound 
may have some steric clashes at the sugar-binding region that could affect its inhibitory 
activity. 5.6.5. Bridged-sugars and sugar phosphates  
The bridged-sugar analogs (ASK1 and ASK2) and sugar phosphate (ASK4) 
showed poor inhibition against kpUGM and mtUGM. The poor inhibitory activity of 
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these compounds could be due to the lack of structural features that can bind at the 
diphosphate and uridine binding region. The majority of the interactions for the natural 
substrate (UDP-Galp) are mediated by the active site residues of the uridine and 
diphosphate binding regions. The poor inhibition of bridged-sugars (ASK1 and ASK2) 
and the sugar phosphate (ASK4) are consistent with the previous inhibition studies of 
various sugar analogs (Richards & Lowary, 2009).  
 5.6.6. Substituted sulfonamides 
Among the substituted sulfonamide derivatives, RIR286 and RIR299 showed the 
best inhibition against kpUGM and mtUGM. The presence of additional hydrogen bond 
donor/acceptor groups and the hydrophobic groups in RIR286 and RIR299 may 
contribute to their improved inhibition compared to RIR163. The positive charge on the 
amino group of RIR163 may have electrostatic repulsion with the active site arginines 
and this could result in poor binding and inhibition. RIR299 showed similar inhibition 
against kpUGM and mtUGM, but RIR286 showed better inhibition against kpUGM. This 
suggests that substitution of different hydrophobic groups in this class of inhibitors can 
alter their specificity. 
5.7 Inhibitory activity towards drUGM WT 
 
In order to use the drUGM:substrate complex structure as a platform for inhibitor 
design, these inhibitors were evaluated for the activity towards drUGM. Inhibition studies 
were done in a manner similar to the studies against kpUGM and mtUGM. Based on the 
overall structural similarity and conserved active site residues between drUGM and other 
bacterial UGMs (Table 4-1), we anticipated that the inhibition profile towards drUGM 
would be similar to kpUGM and mtUGM. But, most of the inhibitors showed poor 
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inhibition (at 1 mM) towards drUGM (Table 5-6). In order to understand this behavior, I 
did a careful analysis of the active site interactions in drUGMox and identified an active 
site asparagine that may play a role in inhibitor binding.  
 
Table 5-6 Inhibition of against drUGM WT and drUGM N372D.  
Compound   % inhibition  
drUGM WT     
 
LQ1    15 (±  5)*     
LQ6    20 (±  2)     
LQ4    44 (± 3)     
LQ8    25 (± 5)    
LQ10    20 (± 5)     
SMC343   27 (± 2)     
RIR163   37 (± 4)                
RIR299   38 (± 2)                
RIR286   42 (± 2)                
ASK1    48 (± 3)                
ASK2    31 (± 3)                
ASK4    30 (± 3)                
ASK5 58 (± 5)                
*
 The errors represent the standard deviation based on duplicate measurements 
 
 
 5.8 Active site comparison and design of drUGM N372D 
 
The active site comparison between drUGM, kpUGM and mtUGM revealed a 
minor difference with respect to one residue (Table 4-1). A conserved aspartic acid 
residue (Asp368 in mtUGM and Asp351 in kpUGM) is replaced by an asparagine residue 
(Asn372) in drUGM. Analysis of the drUGM:substrate complex structure revealed that 
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the Asn372 is involved in hydrogen bond interactions with the sugar moiety of the 
substrate. I proposed that this residue might be involved in inhibitor recognition. To test 
this hypothesis, I mutated the active site Asn372 to aspartic acid (N372D). drUGM 
N372D mutant was prepared by PCR-based site-directed mutagenesis (See section 3.0 
and 3.1). Sequencing results confirmed the presence of desired mutation (N372D). 
5.9 Kinetic characterization of drUGM N372D mutant 
 
In order to determine the kinetic behavior of drUGM N372D towards the 
substrate, kinetic studies on drUGM N372D were carried out and compared the kinetic 
parameters with drUGM WT. The saturation curve and the kinetic parameters are shown 
in Figure 5-9 and Table 5-7 respectively.  
The kcat of drUGM N372D is comparable to drUGM WT, however, Km increased 
by two-fold. The kcat/Km of drUGM WT and N372D mutant are comparable and it can be  
 
 
 
 
 
 
 
 
 
 
   
Figure 5-9 Saturatuion curve for drUGM N372D mutant.  
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concluded that this mutation does not affect the catalytic property of the enzyme towards 
the substrate. 
Table 5-7 Kinetic parameters for drUGM N372D.  
Enzyme kcat(s-1) Km (µM) kcat/ Km (µM-1 s-1) 
drUGM N372D 45 ± 0.7 126 0.4 
drUGM WT 66 ± 2 55 ± 7 1.2 
 
5.10 Structure of drUGM N372D:UDP-Galp complex 
 
Our next goal was to determine if the drUGM N372D mutant binds the substrate 
(UDP-Galp) similar to drUGM WT. drUGM N372D mutant was cocrystallized with 
UDP-Galp using the same conditions that gave drUGM:UDP-Galp complex crystals. The 
drUGM N372D:UDP-Galp complex crystallized in the P212121 space group and the 
crystals diffracted to 2.5 Å resolution. The space group and unit cell dimensions of 
drUGM N372D:UDP-Galp crystals were similar to drUGMox crystals. The data 
collection and refinement statistics for the drUGM N372D:UDP-Galp complex are 
summarized in Table 5-8. The drUGM N372D:UDP-Galp complex was solved using 
drUGMox (without ligands) as the starting model for refinement. The simulated annealing 
difference map revealed electron density for FAD and the nucleotide portion (UDP) of 
the substrate. FAD and UDP were modeled into the density and further rounds of 
refinement were carried out (Figure 5-10). The density for sugar moiety was weak in all 
the chains and this could be due to the poor occupancy of the substrate. This is consistent 
with the drUGMox structure, where the density for sugar moiety was poor when compared 
to drUGMred (See section 4.2) The NCS average map over 10 active sites showed better 
density for the sugar portion of the substrate in the drUGM N372D:UDP-Galp complex. 
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The overall structure of drUGM N372D:UDP-Galp is similar to drUGMox (rmsd of 0.6 Å 
for all equivalent Cα atoms) including the two mobile loops (Figure 5-9). Most 
importantly, the binding mode and active site interactions of UDP-Galp in drUGM 
N372D were similar to drUGM WT. The structure of the drUGM N372D:UDP-Galp 
complex suggests that this mutation did not perturb the substrate binding mode and its 
interactions at the active site.  
Table 5-8 Data collection statistics and refinement. 
 
 
  
drUGM  
N372D:UDP-Galp 
 
Data collection 
 
Space group P212121 
Cell dimensions    
    a, b, c (Å) 133.0, 176.4, 220.7 
 90.00, 90.00, 90.00 
Resolution (Å) 2.50 (2.59-2.50) 
Rsym  18.9 (61.6) 
I / σI 4.7 (1.5) 
Completeness (%) 100 (99.8) 
Redundancy 7.3 
 
 
Refinement  
Resolution (Å) 40.0-2.5 
No. reflections 179222  
Rwork / Rfree 0.22/0.27 
No. atoms  
    Protein 30134 
    Ligand (FAD, UDP and 
UDP-Galp) 
857 
    Water (molecules) 401 
B-factors  
    Protein 53.1 
    Ligand 59.5 (UDP-Galp) 
61.8 (UDP) 
54.7 (FAD)                          
  
    Water 41.5 
r.m.s. deviations  
    Bond lengths (Å) 0.008 
    Bond angles (°) 
 
1.2 
*values in the parenthesis are for the highest resolution shell 
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Figure 5-10 Structure of drUGM N372D:UDP-Galp complex. A) 2Fo-Fc map of UDP-
Galp and FAD. The density of UDP-Galp is weak and similar to that observed in the 
drUGMox complex. B) The overall structure, mobile loop conformation and the binding 
mode of UDP-Galp in drUGM N372D. C) Active site interactions of UDP-Galp in 
drUGM N372D mutant. D) Overlay of drUGMox (blue) and drUGM N372:UDP-Galp 
(red) to highlight the binding mode similarity of in both the complexes.  
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5.11 Inhibition profile against drUGM N372D mutant 
             
Kinetic and structural studies of drUGM N372D mutant confirmed that this 
mutant behaves in a similar way as drUGM WT towards the substrate. Inhibition studies 
were performed with the drUGM N372D to study its behavior towards the inhibitors 
(Table 5-9). It is evident from Table 5-9 that most of the inhibitors showed better 
inhibition towards the drUGM N372D as compared to drUGM WT. Some inhibitors 
showed better activity even at low concentrations. Comparison of the inhibition studies 
between drUGM WT and drUGM N372D mutant suggests that the active site aspartic 
acid plays a role in binding to these inhibitors. However, the structural basis for the 
observed differences in the inhibition profile towards drUGM N372D mutant is unclear at 
this moment.  
5.12 Inhibition against kpUGM D351N mutant 
 
The inhibition profile towards the drUGM N372D mutant revealed the role of an 
active site aspartic acid in inhibitor binding. It is possible that mutation of this active site 
aspartic acid in kpUGM or mtUGM to asparagine may affect the inhibitor binding and 
decrease the % inhibition. kpUGM D351N mutant was designed and prepared by PCR-
based site-directed mutageneis method (See section 3.0 and 3.1). The inhibitory activity 
of one of the promising inhibitors (LQ10) was evaluated with kpUGM D351N. LQ10 
showed only 8 % inhibition at 1.0 µM towards kpUGM D351N, while approximately 50 
% inhibition was observed with kpUGM WT (Table 5-9). This suggests that the active 
aspartic acid residue has a definite role in determining inhibitor specificity.  
5.13 Role of active site aspartic acid 
 The mutation of active site Asn to Asp (N372D in drUGM) and Asp to Asn 
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Table 5-9 Comparion of inhibitory profile between drUGM WT and drUGM N372D.  
Compound     % inhibition  
drUGM WT   drUGM N372D  
 
LQ1    15 (± 5)*    56 (± 1) @10 µM  
LQ6    20 (± 2)    60 (± 3) @ 1.0 µM  
LQ4    44 (± 3)    68 (± 6) 
LQ8    25 (± 7)   49 (± 2) 
LQ10    20 (± 5)   76 (± 2) @ 1 µM  
SMC343   27 (± 2)    36 (± 2) 
RIR163   37 (± 4)               33 (± 5) 
RIR299   38 (± 2)               77 (± 4) 
RIR286   42 (± 2)               37 (± 4)  
ASK1    48 (± 3)               52 (± 3) 
ASK2    31 (± 3)               43 (± 4) 
ASK4    30 (± 3)               38 (± 3) 
ASK5 58 (± 5)               52 (± 8 
-- not determined 
*
 The errors represent the standard deviation based on duplicate measurements  
 
Table 5-10 Inhibition of LQ10 towards kpUGM WT and D351N mutant. 
      % inhibition 
 
                      kpUGM WT    kpUGM D351N 
 
 
LQ10            48 (± 1)      8 (± 2) 
 
*
 The errors represent the standard deviation based on duplicate measurements 
 
(D351N in kpUGM) showed altered specificity towards inhibitors. From a structural 
standpoint, Asn and Asp have similar geometry and can accept/donate hydrogen bonds, 
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but Asp being a carboxylic acid can exist in ionized or unionized states in the active site. 
The ionized state of Asp may participate in strong ionic interactions with the inhibitor 
and improve its binding (as observed with drUGM N372D mutant). The ionized form of 
Asp may be stabilized by an arginine or lysine (located nearby) and lock the 
conformation of Asp. To understand the behavior of the Asn to Asp mutation, I looked 
into the literature for similar mutations and their behavior towards the substrate and 
inhibitor. Indeed, AsnAsp and AspAsn mutants showed significant differences in 
activity and inhibition. AspAsn mutation (D27N) in dihydrofolate reductase (DHFR) 
was carried out to probe the binding of folate analogs, such as methotrexate (MTX) 
(Villafranca et al, 1986). The Kd for MTX towards the D27N increased to 1.9 nM from 
0.07 nM. Structures of WT DHFR:MTX complex and DHFR D27N:MTX complexes 
were determined and the inhibitor binds in an identical orientation in both WT and the 
D27N mutant, although the positions of two active site water molecules showed some 
differences.  
Mutation of an active site AspAsn in phosphodiesterase 4D3  (PDE4D3) 
altered the substrate specificity and inhibition profile (Herman et al, 2000). PDE4D3 
catalyzes the hydrolysis of cyclic AMP (cAMP), a second messenger involved in the cell 
signaling pathways. Asp413 was mutated to Asn (D413N) to probe its role in catalysis 
and inhibitor binding. The Km for D413N mutant was found to be 16 µM (5.8 µM for 
WT). It is reasonable to assume that this mutation did not affect the substrate binding 
significantly.  Most importantly, the D413N mutant was shown to hydrolyze cGMP. A 
direct comparison of kinetic results for the hydrolysis of cGMP by WT and the D413N 
mutant was hampered due to the inability to measure hydrolysis of cGMP by the WT 
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(levels of hydrolysis product were low for WT). The D413N mutant showed resistance or 
a low level of inhibition towards rolipram, a known inhibitor of PDE4. The IC50 value of 
rolipram is 1.0 µM against WT and for the D413N mutant it was found to be 34 µM. The 
structural basis for the altered substrate specificity and inhibitor resistance by the D413N 
mutant is lacking.  
In another study, mutation of an active site asparagine to aspartic acid altered the 
substrate specificity significantly (Liu & Santi, 1992). The enzyme thymidylate synthase 
(TS) catalyzes the reductive methylation of dUMP by tetrahydrofolate (THF) to form 
dTMP and dihydrofolate (DHF). To probe the role of active site asparagine (N229), it 
was mutated to aspartic acid (N229D). The Km of dUMP and THF for N229D mutant 
increased by 3.5 and 10-fold respectively, while kcat decreased by 1000-fold. Nonetheless, 
this mutation altered the substrate specificity from dUMP to dCMP. The N229D mutant 
showed 40-fold higher specificity for dCMP than for dUMP. dCMP is not a substrate for 
TS (WT) and binds very poorly.  
The behavior of the drUGM N372D and kpGM D351N mutants towards the 
inhibitor is not surprising. Precedence for such effects observed in other proteins clearly 
assigns a specific role for the active site aspartic acid in UGM towards inhibitor binding. 
Further structural studies are needed to understand the role of this active site aspartic 
acid.  
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CHAPTER 6  
 
Conclusions 
 
6.0 Conclusions and Future Directions 
 
Structural and inhibition studies on UGM provided valuable information 
regarding the catalytic mechanism and inhibition on this unique enzyme. Our objective of 
using alternate homolog to solve UGM:substrate complex structure was achieved 
successfully through drUGM. Also, I was able to use drUGM for solving other ligand 
complexes. Structures of drUGM in complex with the substrate (UDP-Galp) gave 
insights into the substrate binding modes and conformational changes associated with the 
substrate binding (Chapter 4). The binding mode of UDP-Galp to UGM is unique and not 
observed in other UDP-Galp binding proteins. The structure of drUGMred provided a 
structural basis for the role of FAD in the reaction. The role of mobile loops in stabilizing 
the bound substrate is evident from the drUGM:substrate complex structures. The role of 
two conserved arginines (Arg198 and Arg305) and the tyrosines are evident from the 
drUGM:substrate complex structures and is consistent with the mutagenesis studies on 
kpUGM and ecUGM. In Chapter 4, I also discuss the comparison of the substrate 
complex structures from drUGM with kpUGM. Significant differences in the binding 
mode and mobile loop conformations were observed between the oxidized substrate 
complexes from kpUGM and drUGM. Base on these comparisons, it appears that the 
drUGM:substrate complex structures reported here are a closer approximation of 
productive substrate binding when compared to kpUGM:substrate complex structure. 
In Chapter 4, I discuss how UDP, UMP and UDP-Glc bind to drUGM. The lack 
of the sugar moiety in UDP does not seem to affect the mobile loop movement and exists 
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in a closed conformation similar to drUGM:substrate complex structures. The 
drUGM:UMP structures showed that the absence of  β-phosphate group in UDP does not 
affect the mobile loop closure. The binding of UDP-Glc (discussed in Chapter 4) 
underlines the role and orientation of the C4 hydroxyl group of the sugar moiety and its 
effect on the binding mode and active site interactions. A change from C4 hydoxyl axial 
(UDP-Galp) to C4 hydoxyl equatorial (UDP-Glc) dramatically altered the binding 
orientation of the sugar moiety (UDP-Glc) and the active site interactions. The binding 
mode of UDP-Glc in kpUGM and drUGM is similar, but differences in the mobile loop 
conformation and stabilization by active site arginines were observed. In general, the 
mobile loops in drUGM:ligand complexes adopt a fully closed conformation across all 
the chains, however the mobile loops adopt different conformational states in the 
kpUGM:ligand complexes. Differences in the energetics of loop closure between drUGM 
and kpUGM may account for different conformational states of the mobile loop, however 
the basis for this difference is unclear. 
 In Chapter 5, results from the design and screening of inhibitors from two 
different approaches, ligand-based and structure-based methods were discussed. The 
activity of GCP, the phosphonate analog of UDP-Galp (ligand-based design) was 
screened against various bacterial UGMs and showed only weak inhibition. The unique 
binding mode and loss of stabilization by the active site arginines (Arg198 and Arg305) 
account for the weak activity of GCP. The drUGM:GCP complex structure underlines the 
consequence of substrate guided design (phosphonate analogs) of  inhibitors for UGM. 
Although phosphonate analogs of natural substrates have proven to be successful for 
other enzymes, UGM seems to be an exception. In Chapter 5, I also discuss the 
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identification of some novel inhibitors of UGM through SBVS. The promising inhibitors 
showed activity close to 1.0 µM and share a common indole scaffold. Docking studies 
allowed us to predict the binding mode of these indole-based inhibitors (LQ1, LQ6 and 
LQ10). The indole nucleus showed stacking interactions with the Tyr179 and Phe176, an 
interaction observed with the uracil ring of the substrate. The hydrazine moiety and the 
tail portion of the inhibitor interact with other active site residues. The indole-based 
inhibitors are promising candidates or lead molecules for further optimization of potency.  
The closed conformation of the mobile loop is considered as a productive 
conformation for UGM and hence docking of inhibitors were done using the closed 
conformation of the mobile loop. However, one cannot rule out the possibility of 
inhibitors binding to UGM with open conformation of the mobile loop. Precedence for 
such inhibitors for UGM is currently not known. Crystal structures UGM in complex 
with the indole-based inhibitors (LQ6 or LQ10) may provide information on the 
conformational state of the mobile loop (open vs closed) and can further assist in the 
inhibitor design. 
 Inhibition studies with drUGM WT and drUGM N372D mutant revealed the role 
of an active site aspartic acid in inhibitor binding. Muation of N372  Asp (drUGM 
N372D) did not affect substrate binding and catalytic activity significantly. Most of the 
inhibitors showed better activity towards drUGM N372D mutant as compared to drUGM 
WT suggestive of the importance of this residue. To probe the role of this aspartic acid in 
kpUGM, I mutated it to asparagine (kpUGM D351N) and screened against LQ10. The 
inhibitory activity of LQ10 towards kpUGM D351N mutant dropped significantly as 
compared to the kpUGM WT. The inhibition studies with drUGM N372D and kpUGM 
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D351N assign a role for active site aspartic acid, although the structural basis of its role 
in inhibitor binding is unclear. 
 The structural and enzyme inhibition studies on UGM reported here have opened 
new questions or directions for further investigations.    
6.1 Kinetic characterization of drUGM active site mutants 
Based on the drUGM:UDP-Galp complex structures, other active site residues 
were identified that are involved in the substrate binding. The role of these active site 
residues have not been studied before in any UGM. Notably, Arg364 located in the FAD 
binding domain has moved towards the substrate binding pocket, whereas, in unliganded 
structures (kpUGM, ecUGM and mtUGM) the corresponding arginine is interacting with 
the phosphate group of the FAD. Towards this goal (to understand the role of other active 
site amino acids in substrate binding and catalysis), I have prepared these mutants by 
PCR-based site-directed mutagenesis and sequencing studies confirmed the desired 
mutation. The clones were transformed into E. coli expression strain and are ready for 
expression, purification and kinetic characterization. These active site-mutants would 
provide insights onto the role of these active site residues in substrate binding and 
catalysis. 
6.2 Crystallization of unliganded drUGM  
Until now, I am unable to determine the structure of unliganded drUGM. This 
structure would provide valuable information on the conformational changes in 
comparison to the drUGM:substrate complex. For example the mobile loop conformation 
and the side chain orientations of some active site residues (Arg364 and Tyr370). 
Crystals of unliganded drUGM diffracted to only 5.0 Å and hence further optimization to 
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improve the diffraction is required. Alternatively, the active site mutants of drUGM can 
be used to crystallize unliganded drUGM. 
6.3 Crystallization of UGM-inhibitor complexes 
 
Inhibition studies on various bacterial UGMs led to the identification of some 
novel indole-based inhibitors. To understand the binding mode and active site 
interactions of these inhibitors, crystal structures of UGM-inhibitor complexes needs to 
determined. The choice of UGM for structural investigations could be the drUGM 
N372D mutant as it showed activity comparable to the kpUGM and mtUGM. Moreover, 
I have shown in Chapter 4 that drUGM can be used as a model for understanding 
bacterial UGM. In addition, drUGM:ligand complexes crystallized easily relative to other 
bacterial UGMs; however, one could also attempt to crystallize these inhibitors with 
kpUGM. Sufficient quantity of LQ6 (indole-based inhibitor) is available for 
cocrystallization or soaking. Initial attempts to crystallize the drUGM N372D:LQ6 
complex gave crystals (using conditions similar to drUGM:substrate) that diffracted to 
only 4.5 Å. The structure of the UGM:LQ6 complex would provide valuable information 
on inhibitior binding, notably the role of aspartic acid and should assist in the structure-
guided optimization of these inhibitors.  
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